medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Authors: Lena Tschiderer (Medical University of Innsbruck) Sanne Peters (University Medical Center Utrecht) Yvonne van der Schouw (University Medical Center Utrecht) Anniek van Westing (University Medical Center Utrecht) Tammy Tong (University of Oxford) Peter Willeit (Medical University of Innsbruck) Lisa Seekircher (Medical University of Innsbruck) Conchi Moreno Iribas (Instituto de Salud Pública de Navarra, Departamento de Salud, Gobierno de Navarra) José María Huerta (Murcia Regional Health Council) Marta Crous-Bou (Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL)) Martin Söderholm (Lund University) Matthias Schulze (German Institute of Human Nutrition) Cecilia Johansson (Umeå University) Sara Själander (Umeå University) Alicia Heath (Imperial College London) Alessandra Macciotta (University of Turin) Christina Dahm (Aarhus University) Daniel Ibsen (Aarhus University) Valeria Pala (Fondazione IRCCS Istituto Nazionale dei Tumori) Lene Mellemkjær (Danish Cancer Society Research Center) Stephen Burgess (University of Cambridge) Angela Wood (Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, United Kingdom) Rudolf Kaaks (German Cancer Research Center (DKFZ)) Verena Katzke (German Cancer Research Center (DKFZ)) Pilar Amiano (Ministry of Health of the Basque Government) Miguel Rodríguez-Barranco (Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA, Universidad de Granada, Granada, Spain) Gunnar Engström (Lund University) Elisabete Weiderpass (International Agency for Research on Cancer) Anne Tjønneland (Danish Cancer Society) Jytte Halkjær (Danish Cancer Society Research Center) Salvatore Panico (Università Federico II Napoli) John Danesh (University of Cambridge) Adam S. Butterworth (University of Cambridge) N. Charlotte Onland-Moret (Julius Center for Health Sciences & Primary Care, University Medical Center, Utrecht)

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Age at menopause and the risk of stroke:

Age at menopause and the risk of stroke: Observational and Mendelian Randomization analysis in 204,244 postmenopausal women

Lena Tschiderer, PhD,^{1,2} Sanne AE Peters, PhD,^{1,3,4} Yvonne T van der Schouw, PhD,¹ Anniek C van Westing, MSc,^{1,5} Tammy YN Tong, PhD,⁶ Peter Willeit, PhD,^{2,7} Lisa Seekircher, DI,² Conchi Moreno-Iribas, PhD,^{8,9,10} José María Huerta, PhD,^{11,9} Marta Crous-Bou, PhD,^{12,13} Martin Söderholm, PhD,^{14,15} Matthias B Schulze, DrPH,^{16,17} Cecilia Johansson, MD,¹⁸ Sara Själander, MD, PhD,¹⁹ Alicia K Heath, PhD,²⁰ Alessandra Macciotta, MSc,²¹ Christina C Dahm, PhD,²² Daniel B Ibsen, PhD,^{22,23,24,25} Valeria Pala, ScD,²⁶ Lene Mellemkjær, PhD,²⁷ Stephen Burgess, PhD,^{7,28,29} Angela Wood, PhD,⁷ Rudolf Kaaks, PhD,³⁰ Verena Katzke, PhD,³⁰ Pilar Amiano, PharmD, MSc,^{31,32,9} Miguel Rodriguez-Barranco, BSc, PhD,^{33,34,9} Gunnar Engström, PhD,¹⁵ Elisabete Weiderpass, PhD,³⁵Anne Tjønneland, MD, PhD, DMSc,^{27,36} Jytte Halkjær, PhD,²⁷ Salvatore Panico, MD,³⁷ John Danesh, PhD,^{38,39,40,41,42,43} Adam Butterworth, PhD,^{7,28,44,45,42} N Charlotte Onland-Moret, PhD¹

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; ²Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria; ³The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom; ⁴The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; ⁵Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands; ⁶Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom; ⁷Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 8Instituto de Salud Pública y Laboral de Navarra, 31003 Pamplona, Spain; ⁹Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029 Madrid, Spain; ¹⁰Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain; ¹¹Department of Epidemiology, Murcia Regional Health Council-IMIB, Murcia, Spain; ¹²Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona 08908, Spain; ¹³Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; ¹⁴Department of Neurology, Skåne University Hospital, Lund and Malmö, Malmö, Sweden; ¹⁵Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden; ¹⁶Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; ¹⁷Institute of Nutritional Science. University of Potsdam, Nuthetal, Germany; ¹⁸Skellefteå Research Unit, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Västerbotten, Sweden; ¹⁹Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden; ²⁰Department of Epidemiology and Biostatistics, School of Public Health,

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CCrBY 4.0 Internationablicanse Imperial College London, London, United Kingdom; Centre for Biostatistics,

Epidemiology, and Public Health (C-BEPH), Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; ²²Department of Public Health, Aarhus University, Aarhus, Denmark; ²³Steno Diabetes Center Aarhus, Aarhus, Denmark; ²⁴MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom; ²⁵Department of Nutrition, Exercise and Sports, University of Copenhagen, Frederiksberg, Denmark; ²⁶Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy; ²⁷Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark; ²⁸Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom; ²⁹MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ³⁰Division of Cancer Epidemiology, German Cancer Research Center, DKFZ, 69120 Heidelberg, Germany; ³¹Ministry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain; ³²Biodonostia Health Research Institute, Epidemiology of Chronic and Communicable Diseases Group, San Sebastian, Spain; ³³Escuela Andaluza de Salud Pública (EASP), 18011 Granada, Spain; ³⁴Instituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain; ³⁵International Agency for Research on Cancer, World Health Organization, Lyon, France; ³⁶Department of Public Health, Section of Environmental Health, Faculty of Health and Medical Sciences, University of Copenhagen, DK-1353 Copenhagen, Denmark; ³⁷School of Medicine, Federico II University, Naples, Italy; ³⁸BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ³⁹National Institute for Health and Care Research Cambridge Biomedical Research Centre, Cambridge University Hospitals, Cambridge, United Kingdom; ⁴⁰The National Institute for Health and Care Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom; ⁴¹Human Genetics, Wellcome Sanger Institute, Saffron Walden, United Kingdom; ⁴²Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, United Kingdom; ⁴³British Heart Foundation Centre of Research Excellence, Division of Cardiovascular Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom; ⁴⁴NIHR Blood and Transplant Research Unit in Donor Health and Behaviour. University of Cambridge, Cambridge, United Kingdom; ⁴⁵BHF Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, Cambridge, United Kingdom

Short title: Age at menopause and the risk of stroke

Correspondence to:

Yvonne T van der Schouw Julius Center for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands Tel: +31 (0) 631118668; Email: y.t.vanderschouw@umcutrecht.nl

Word count: 4,848; 2 Tables; 3 Figures

1 Abstract

Background: Observational studies have shown that women with an early menopause are at higher risk of stroke compared to women with a later menopause. However, associations with stroke subtypes are inconsistent and the causality is unclear. Therefore, we conducted a large-scale analysis to investigate the observational association between age at menopause and different types of stroke accompanied by a Mendelian Randomization analysis to evaluate causality.

8 Methods: We analyzed data of the UK Biobank and EPIC-CVD study. 9 Postmenopausal women without a history of stroke at baseline were eligible for 10 inclusion. The study endpoints were total stroke and stroke subtypes (i.e., ischemic 11 stroke, hemorrhagic stroke, intracerebral hemorrhage, and subarachnoid 12 hemorrhage). We investigated the observational association between age at 13 menopause and risk of stroke using Cox-regression analysis in each study separately 14 before combining effect sizes using random-effects meta-analysis. Cox-regression 15 analyses were progressively adjusted for (1) age, (2) smoking status, body mass index, 16 glycated hemoglobin, total cholesterol, and hypertension, and (3) ever use of hormone 17 replacement therapy and age at menarche. We used two-sample Mendelian 18 Randomization analysis to study whether there is a causal relationship between 19 genetically proxied age at menopause and risk of stroke.

Results: A total of 204,244 women were included (7,883 from EPIC-CVD [5,292 from the sub-cohort]; 196,361 from the UK Biobank). Pooled mean baseline age was 58.9 years (SD 5.8) and pooled mean age at menopause was 47.8 years (SD 6.2). Natural menopause occurred in 77.6% of all women. Over a median follow-up of 12.6 years (IQR 11.8, 13.3), 6,770 women experienced a stroke. In multivariable adjusted observational analyses, the pooled hazard ratios per five years younger age at

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 menopause were 1.09 (95% CI: 1.07, 1.12) for stroke, 1.09 (1.06, 1.13) for ischemic

- 27 stroke, 1.10 (1.04, 1.16) for hemorrhagic stroke, 1.14 (1.08, 1.20) for intracerebral
- 28 hemorrhage, and 1.00 (0.84, 1.20) for subarachnoid hemorrhage. The Mendelian
- 29 Randomization analysis found no evidence for a causal relationship between
- 30 genetically proxied age at menopause and risk of any type of stroke.
- 31 **Conclusions:** Earlier age at menopause is associated with, but not causally related to
- 32 the risk of stroke.

33 Clinical Perspective

34 What is new?

This analysis involves over 200,000 postmenopausal women and more than
 6,000 incident stroke cases and investigates the observational association
 between age at menopause and various subtypes of stroke. Furthermore, a
 Mendelian Randomization analysis was conducted to study whether
 associations are causal or not.

Earlier age at menopause was statistically significantly associated with a higher
 risk of stroke and its subtypes ischemic stroke, hemorrhagic stroke, and
 intracerebral hemorrhage. We found no statistically significant relationship
 between earlier or later age at menopause and risk of subarachnoid
 hemorrhage.

- The Mendelian Randomization analysis suggested no causal effect of
 genetically proxied age at menopause and risk of any type of stroke.
- 47

What are the clinical implications?

- Women with earlier age at menopause are at higher risk of stroke. The
 underlying reasons need to be further investigated.
- Our analysis suggested that earlier menopause *per se* does not cause stroke.
 For prevention and adequate treatment of stroke in women, a better
 understanding of the specific role of menopause and the mechanistic
 background that leads to higher risk of stroke is needed.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Non-standard Abbreviations and Acronyms

55	CI	Confidence interval
56 57	EPIC-CVD	European Prospective Investigation into Cancer and Nutrition- Cardiovascular Diseases
58	GWAS	Genome-wide association study
59 60	InterLACE	International Collaboration for a Life Course Approach to Reproductive Health and Chronic Disease Events
61	IQR	Interquartile range
62	IVW	Inverse variance weighted
63	HbA1c	Glycated hemoglobin
64	HR	Hazard ratio
65	HRT	Hormone replacement therapy
66	SD	Standard deviation
67	SNP	Single nucleotide polymorphism
68	UKB	UK Biobank

69 Introduction

70 Stroke is the second leading cause of death worldwide and was responsible for over 71 six million deaths in 2019.¹ At a global level, the proportion of deaths caused by stroke 72 is higher for women (12.5% in 2019) than for men (10.9% in 2019).² Women and men 73 are also prone to different types of stroke. In a large-scale study in over nine million 74 individuals, men had a higher risk of developing ischemic stroke, transient ischemic 75 attack, and intracerebral hemorrhage, while women were at higher risk of 76 subarachnoid hemorrhage.³ Women and men share several risk factors for stroke but 77 the strengths of associations can differ between sexes.⁴ In addition, the relationship of 78 various female-specific factors with cardiovascular risk has recently received 79 increasing attention.⁵

80 The transition to menopause is predominantly defined by hormonal changes, and is 81 accompanied by multi-faceted symptoms, such as sleep disturbances and vasomotor dvsfunction.⁶ Recent data suggest a relationship between earlier menopause and the 82 risk of developing cardiovascular disease.^{7,8} A large-scale individual participant data 83 84 meta-analysis of the International Collaboration for a Life Course Approach to 85 Reproductive Health and Chronic Disease Events (InterLACE) consortium found a 86 higher risk of developing stroke in women with earlier age at natural menopause.⁹ The 87 hazard ratio (HR) for stroke was 1.72 (95% confidence interval [CI]: 1.43, 2.07) for 88 women who experienced menopause before the age of 40 years compared to women 89 who experience menopause at age 50 or 51 years.⁹ The majority of previous studies 90 on age at menopause and risk of stroke focused on a combined stroke endpoint or 91 analyzed broader categories of ischemic and hemorrhagic stroke rather than specific 92 stroke subtypes.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 Since associations between age at menopause and risk of stroke have been based on

94 data from observational studies, which are prone to confounding, the causality of the associations is unclear. Importantly, although earlier menopause is also associated 95 with a higher risk of coronary heart disease,⁹ we showed in a recent Mendelian 96 Randomization analysis that this association is unlikely to be causal.¹⁰ Furthermore, a 97 98 Mendelian Randomization analysis based on publicly available results reported no 99 significant causal relationship between genetically proxied age at natural menopause 100 and risk of coronary artery disease or stroke.¹¹ Similarly, a recently published study 101 demonstrated no causal association between age at natural menopause and risk of 102 ischemic stroke, although a small number of genetic variants was used.¹² Whether this 103 is also true for other types of stroke is still unclear.

We conducted a large-scale analysis including 204,244 postmenopausal women from the UK Biobank (UKB) and European Prospective Investigation into Cancer and Nutrition-Cardiovascular Diseases (EPIC-CVD) study to quantify the observational association between age at menopause and different types of stroke, and to investigate whether these associations were likely to be causal by applying a Mendelian Randomization analysis.

110 Methods

111 Study participants

In the present analysis, we included data from the UKB and EPIC-CVD study. Further details about these studies have been published previously.^{13–16} In brief, the UKB is a large-scale prospective study in the UK in which over 500,000 individuals aged 40 to 69 years were recruited between 2006 and 2010.^{13,14} The UKB was approved by the North West Multi-Centre Research Ethics Committee and all participants provided written informed consent. EPIC-CVD is a case-cohort study nested in the prospective

cohort study EPIC, which recruited more than 500,000 individuals between 35 and 70 118 years of age in 1992-2000 from 23 centers throughout Europe.^{15–17} For the case-cohort 119 120 study EPIC-CVD, a random sub-cohort was selected from the EPIC study for which a 121 variety of biomarkers were obtained. In addition, EPIC-CVD includes all incident 122 coronary heart disease and stroke events that occurred outside the sub-cohort. The 123 EPIC study complies with the Declaration of Helsinki, and all participants gave written 124 informed consent before participating. The study was approved by the local ethics 125 committees of the participating centers and the Institutional Review Board of the 126 International Agency for Research on Cancer (IARC, Lyon).

127 For the current analysis, postmenopausal women free of history of stroke at study 128 baseline were eligible for inclusion. Furthermore, for EPIC-CVD, we excluded women 129 with incident coronary heart disease and without incident stroke outside the sub-cohort 130 due to the case-cohort design of study. Figure 1 provides a flow chart on the selection 131 of participants contributing to the current analysis. Of the 35,455 EPIC-CVD 132 participants, we excluded 16,788 men, 632 women from French centers because 133 follow-up for stroke was unavailable, 87 from Norway because important covariates 134 were not measured, and 1,034 from Greece due to administrative constraints. 135 Furthermore, we excluded 4,283 women with incident coronary heart disease outside 136 the EPIC-CVD sub-cohort, 29 women with a history of stroke at baseline, and 4,719 137 women who were not postmenopausal, leaving 7,883 EPIC-CVD participants 138 contributing to the current analysis. Of these 7,883 postmenopausal women, 5,292 139 belonged to the sub-cohort and 2,591 were stroke cases outside the sub-cohort (with 140 147 further stroke cases also belonging to the sub-cohort). Of the 502,412 individuals 141 from UKB, 229,086 were excluded because they were male, 3,732 because they had 142 a history of stroke at baseline, and 73,233 because they were not postmenopausal at 143 baseline leaving 196,361 UKB participants contributing to our analysis. Consequently,

144 we included a total of 204,244 postmenopausal women from both studies in the

145 observational analysis.

146 **Definition of menopause, age at menopause, and type of menopause**

147 Women were defined as being postmenopausal if they fulfilled at least one of the 148 following criteria: (1) experienced natural menopause (defined as stopping of periods 149 in UKB and as reporting no menses for one year or longer due to natural menopause 150 in EPIC-CVD), (2) had had a unilateral or bilateral ovariectomy in EPIC-CVD or bilateral 151 ovariectomy in UKB, or (3) had had a hysterectomy. Moreover, where no information 152 on menopausal status was provided, we defined women aged >54 years as postmenopausal, as suggested previously.¹⁰ Type of menopause was defined as 153 154 surgical if a history of ovariectomy or hysterectomy had been reported and as natural, 155 otherwise. Age at menopause was defined as age of a woman's last menstruation or, 156 in case of a surgical menopause, the age at ovariectomy or hysterectomy.

157 Outcome definition

158 We analyzed a combined stroke endpoint including fatal and non-fatal ischemic and 159 hemorrhagic stroke with ICD-10 codes I60, I61, I63, and I64. Furthermore, we analyzed 160 the individual stroke endpoints ischemic stroke (163, 164), hemorrhagic stroke (160, 161 161), intracerebral hemorrhage (161), and subarachnoid hemorrhage (160). For UKB 162 participants, September 30, 2021, was used as end of follow-up for stroke. In EPIC-163 CVD, end of follow-up for stroke varied between the centers ranging from 2003 to 2010. 164 Time to event was defined as time to stroke, death, or end of follow-up, whichever 165 occurred first. For the analysis of stroke sub-types, we censored individual stroke 166 events against each other and defined time to stroke as time to the first individual stroke endpoint. For instance, if an individual experienced both ischemic and 167 168 hemorrhagic stroke, we only analyzed the first stroke event that occurred during follow-

169 up. In case two types of stroke occurred on the same day, we gave preference to

170 ischemic stroke over intracerebral hemorrhage over other types of stroke.

171 Details about the assessment and definition of additional variables used in our 172 analyses are described in the **Supplementary Methods**.

173 Genetic data

We obtained individual-level imputed data on genetic variants from both EPIC-CVD and UKB. Genotyping in EPIC-CVD was performed using the Human Core Exome array, Illumina 660 Quad array, and Omni Exome Express array.¹⁸ In the UKB, participants were genotyped with the Affymetrix UK BiLEVE Axiom array and the Affymetrix UKB Axiom Array.^{14,19} Genotype imputation was performed using the Haplotype Reference Consortium for EPIC-CVD¹⁸ and the Haplotype Reference Consortium as well as the UK10K haplotype reference panel for the UKB²⁰.

181 For the Mendelian Randomization analysis, to quantify genetically proxied age at 182 menopause, we used genetic variants reported to be associated with age at 183 menopause by a large-scale genome-wide association study (GWAS) for our 184 instrumental variable.¹¹ A detailed selection process of the single nucleotide 185 polymorphisms (SNPs) is described in the **Supplementary Methods**. Of the 290 SNPs 186 identified by the GWAS, we excluded 124 SNPs because they were unavailable 187 (n=63), palindromic (n=16), or rare with minor allele frequencies <0.1 (n=45), and used 188 the remaining 166 SNPs to determine genetically proxied age at menopause in our 189 main Mendelian Randomization analysis (see **eFigure 3** and **eTable 1**).

As shown in **Figure 1**, from the 204,244 postmenopausal women included in our observational analysis, we excluded 2,140 women from EPIC-CVD and 6,468 women from the UKB because data on the SNPs included in our analysis were unavailable, leaving 195,636 women included in our Mendelian Randomization analysis.

194 Statistical analysis

195 **Descriptive statistics**

Summary statistics of continuous variables are provided as means and standard deviations (SDs) if normally distributed or as medians and interquartile ranges (IQRs), otherwise. Categorical variables are summarized as numbers and percentages. Pooled means across both cohorts were obtained from random-effects meta-analysis. To enhance comparability, we provide descriptive statistics including EPIC-CVD participants from the sub-cohort only.

202 **Observational analyses**

203 For the observational analysis, we estimated the association between age at 204 menopause and incidence of stroke using Cox-regression analysis. For UKB, we 205 implemented a Cox proportional hazards model. For EPIC-CVD, we additionally took 206 into account the case-cohort design of the study by implementing Prentice-weighted 207 Cox-regression analysis with robust standard errors.²¹ For both studies, we used age 208 at baseline as the underlying time scale. We investigated the relationship between age 209 at menopause and risk of stroke implementing age at menopause as a continuous 210 variable and also by categorizing it as <40, 40 to <45, 45 to <50, 50 to <55, and \geq 55 211 years, using 50 to <55 years at menopause as the reference category. When analyzing 212 age at menopause as a categorical variable, we also obtained P-values for linear 213 trends by treating the categorical variable as a continuous variable in our model. 214 Furthermore, we present 95% CIs for each category using guasi variances to enhance 215 the comparison between individual categories.²² When analyzing age at menopause 216 as a continuous variable, we reported HRs per five years younger age at menopause. 217 For graphical demonstration purposes and to assess non-linearity, we also analyzed 218 age at menopause using restricted cubic splines with three knots at 45, 50, and 55

years of age at menopause using an age of 50 years at menopause as reference. We

219

220 progressively adjusted our analysis for (1) age at baseline (Model 1), (2) smoking 221 status (never, ex, current), body mass index (kg/m²), glycated hemoglobin (HbA1c, %), 222 total cholesterol (mmol/L), and hypertension (yes, no) at baseline (Model 2), and (3) 223 ever use of hormone replacement therapy (HRT) at baseline (yes, no) and age at 224 menarche (years) (Model 3). For EPIC-CVD, we additionally stratified all models by 225 country. Finally, we combined study-specific results using random-effects meta-226 analysis when including age at menopause as continuous variable, and multivariate 227 random-effects meta-analysis²³ when analyzing it as categorical variable. We also used multivariate random-effects meta-analysis²³ to combine beta coefficients of the 228 229 restricted cubic splines model. We imputed missing values using multiple imputation 230 by chained equations with 14 datasets and 30 iterations (see Supplementary 231 Methods for more details).

232 We estimated HRs for risk of stroke per five years younger age at menopause across 233 the following subgroups: use of HRT (ever vs never), type of menopause (surgical vs 234 natural), smoking status (current, ex vs never), and age at baseline. We included age 235 at menopause, the subgroup variable of interest, and a formal interaction term between 236 age at menopause and the subgroup variable of interest into our model. In addition, 237 we adjusted the models for the baseline variables age, smoking status, body mass 238 index, HbA1c, total cholesterol, hypertension, ever use of HRT, and age at menarche, 239 if appropriate. For illustrative purposes we categorized age at baseline into <60 vs ≥60 240 years. The P-value for interaction for age at baseline was obtained from a model in 241 which age at baseline was included as a continuous variable. For EPIC-CVD, we 242 additionally stratified the model by country. We obtained effect estimates in each study 243 and combined them using multivariate random-effects meta-analysis.²³

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Mendelian Randomization analysis

244

245 For the effect of the genetic variants on age at menopause, we used the beta 246 coefficients and standard errors reported by the GWAS published by Ruth et al.¹¹ 247 without the UKB data in order to avoid sample overlap. We transformed beta 248 coefficients and standard errors to reflect genetic effects per five years age at 249 menopause to enhance comparability to our observational analysis. Then, we 250 investigated the strength of our genetic instrument based on the F-statistic. For both 251 EPIC-CVD and UKB, the F-statistic was calculated from linear regression including all 252 genetic variants as independent variables and age at menopause as the dependent 253 variable using the first imputed dataset and only including individuals from the sub-254 cohort for EPIC-CVD. Next, we estimated the effect of genetically proxied age at 255 menopause and risk of different types of stroke using Cox-regression analysis with age 256 as the underlying time scale. For UKB, we adjusted our model for age at baseline and the first 16 genetic principal components as suggested by Privé et al.²⁴ For EPIC-CVD, 257 258 we adjusted our model for age at baseline, the first ten genetic principal components 259 (as 16 were not available), and genotype array, stratified by country, and implemented Prentice-weighted Cox-regression.²¹ We obtained effect estimates and standard errors 260 261 for the association of each SNP with risk of different types of stroke. Finally, we 262 conducted the Mendelian Randomization analysis based on (1) the effect estimates of the association between the SNPs and risk of different types of stroke we obtained 263 264 from the UKB and EPIC-CVD and (2) the GWAS summary effect estimates on the 265 relationship between the SNPs and age at menopause using the R-package 266 MendelianRandomization.²⁵ We applied standard inverse-variance weighted (IVW) 267 regression to obtain the effect estimates for the association of genetically proxied age 268 at menopause with risk of different types of stroke. We combined the effect sizes 269 across studies using fixed-effect meta-analysis.

 medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 We conducted several sensitivity analyses. First, we applied different Mendelian 270 271 Randomization analysis methods including simple median regression, weighted 272 median regression, and MR-Egger regression. Second, we conducted a leave-one-out 273 analysis omitting each SNP in turn to identify whether one of the SNPs particularly 274 drives the result. Third, to study the distribution of stroke-related and female-specific 275 factors across genetically proxied age at menopause, we obtained a polygenic risk score by calculating a weighted sum of the SNPs used in our analysis, weighting each 276 277 SNP with the corresponding summary effect size obtained from the GWAS. We divided the polygenic risk score into study-combined fifths (fifths were comparable between 278 279 the two studies) and compared the variables smoking status, body mass index, HbA1c, 280 total cholesterol, hypertension, ever use of HRT, and age at menarche, across the five 281 categories. Fourth, we further investigated pleiotropy by implementing MR-PRESSO.²⁶ 282 Fifth, to consider the effect of rare genetic variants, we excluded SNPs with minor allele 283 frequencies <0.01 (n=8), rather than those with minor allele frequencies <0.1 as we 284 did in our primary analysis. This sensitivity analysis included 203 SNPs, which are 285 listed in eTable 1. Sixth, we additionally adjusted our Mendelian Randomization 286 analysis for phenotypes associated with cardiovascular risk, i.e., smoking status, body 287 mass index, HbA1c, total cholesterol, hypertension, ever use of HRT, and age at 288 menarche.

Statistical analyses were carried out using R 4.0.5 (The R Foundation, Vienna,
Austria). All statistical tests were two-sided and P-values ≤0.05 were deemed as
statistically significant.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

292 **Results**

293 Study population

294 Baseline characteristics of the study participants are demonstrated in Table 1, 295 separately for the EPIC-CVD sub-cohort and UKB, and pooled across both cohorts. 296 Overall, mean age was 58.9 years (SD 5.8) at baseline and 47.8 years (SD 6.2) at 297 menopause. Surgical menopause was reported by 22.4% of the participants. Mean 298 age at surgical and natural menopause was 41.9 (SD 7.0) and 49.8 (SD 4.6), 299 respectively. Moreover, 51.3% of the women had a history of hypertension, 33.3% of 300 the women smoked previously, and 8.7% smoked currently. Half of the women 301 reported to have used HRT during their lifetime.

302 **Observational analysis**

303 Over a median follow-up of 12.6 years (IQR 11.8, 13.3; 13.0 [10.8, 14.3] in EPIC-CVD 304 and 12.6 [11.8, 13.3] in UKB), 6,770 women experienced a stroke. Of those, 5,155 305 were ischemic and 1,615 were hemorrhagic (976 intracerebral hemorrhages and 639 306 subarachnoid hemorrhages). Of the 6,770 strokes, 2,738 occurred in EPIC-CVD and 307 4,032 in UKB. Pooled results on the association of age at menopause with risk of stroke 308 are provided in **Table 2** and **Figure 2**. Each five years younger at menopause was 309 associated with a higher risk of total stroke (most adjusted HR 1.09 [95% CI: 1.07, 310 1.12]), ischemic stroke (1.09 [1.06, 1.13]), hemorrhagic stroke (1.10 [1.04, 1.16]), and 311 intracerebral hemorrhage (1.14 [1.08, 1.20]). Age at menopause was not associated 312 with the risk of subarachnoid hemorrhage (most adjusted HR 1.00 [0.84, 1.20] for each 313 five years younger). Age at menopause was approximately log-linearly associated with 314 the risk of stroke (P-value for trend < 0.001), ischemic stroke (P-value for trend < 0.001), 315 hemorrhagic stroke (P-value for trend 0.022), and intracerebral hemorrhage (P-value 316 for trend <0.001). For instance, compared to women who had experienced menopause medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. between 50 and <55 years, multivariable adjusted HRs for stroke were 1.42 (1.28,

between 50 and <55 years, multivariable adjusted HRs for stroke were 1.42 (1.28, 1.56), 1.23 (1.14, 1.33), 1.10 (1.02, 1.19), and 0.96 (0.84, 1.10) in women who had experienced menopause at ages <40, 40 to <45, 45 to <50, and \geq 55 years, respectively. Separate results for EPIC-CVD and UKB are shown **eTable 2** and **eTable** 3, respectively. Results for all subtypes of stroke, except subarachnoid hemorrhage

322 (higher risk for younger age at menopause in UKB but not in EPIC-CVD), were highly

323 consistent between EPIC-CVD and UKB as demonstrated in **eFigure 1**.

eFigure 2 provides results of subgroup analyses for each individual stroke endpoint according to age at baseline, smoking status, use of HRT, and type of menopause. Age at baseline modified the association between age at menopause and total stroke (P-value for interaction 0.010) and ischemic stroke (P-value for interaction 0.003) with higher HRs for younger postmenopausal women. We did not find any statistically significant modification across all other subgroups (all P-values >0.05).

330 Mendelian Randomization analysis

331 The F-statistics for the 166 SNPs included in our Mendelian Randomization analysis 332 were 1.31 (R²: 5.2%) in EPIC-CVD and 23.2 (R²: 2.0%) in UKB.

Results of the Mendelian Randomization analysis are provided in Figure 3 (see eTable
4 for study-specific results). In contrast to the observational analysis, the IVW
regression showed no evidence for a causal effect of age at menopause on stroke risk
(HR per five years younger genetically proxied age at menopause 0.95 [95% CI: 0.82,
1.09; P-value=0.445]), nor for any of the individual stroke endpoints ischemic stroke,
hemorrhagic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage (all Pvalues>0.05).

340 Sensitivity analyses

341 The results of the Mendelian Randomization analyses were similar when applying 342 simple median, weighted median, and MR-Egger regression (see Figure 3 and eTable 343 4). Furthermore, leave-one-out analyses showed robust associations when excluding 344 each SNP in turn (data not shown). The MR-Egger method did not show any evidence 345 for pleiotropy (P-values of intercept >0.05, see **Figure 3** and **eTable 4**). Furthermore, 346 MR-PRESSO did not yield any SNPs that produced significant horizontal pleiotropy. 347 After only excluding rare SNPs with minor allele frequencies <0.01 we again found no 348 statistically significant relationship between genetically proxied age at menopause and 349 risk of stroke as demonstrated in **eFigure 4**. Data on baseline patient characteristics 350 across fifths of the polygenic risk score are provided in **eTable 5** (see distribution 351 across age at menopause categories in eTable 6). There appeared to be an 352 association between genetically proxied age at menopause and hypertension and ever 353 use of HRT. However, when we adjusted our Mendelian Randomization analysis for 354 all phenotypes, the association between genetically proxied age at menopause and 355 risk of different types of stroke remained statistically nonsignificant as shown in 356 eFigure 5.

357 **Discussion**

358 In this large-scale analysis, we found an association between earlier age at 359 menopause and higher risk of stroke, which was not likely to be causal according to 360 Mendelian Randomization analysis.

361 Strengths and limitations

362 Our study has several strengths. First, we included a large sample of postmenopausal 363 women in our observational analyses and more than 6,000 incident stroke events 364 providing excellent statistical power to detect associations and the potential influence

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. of a variety of predefined, Clinically relevant characteristics. Second, we investigated

365

366 several subtypes of stroke including ischemic and hemorrhagic stroke and 367 intracerebral and subarachnoid hemorrhage. Third, we meta-analyzed data from two 368 large-scale studies and found highly consistent results for all stroke endpoints except 369 subarachnoid hemorrhage, which may be explained by limited statistical power for this 370 subtype. Fourth, we applied Mendelian Randomization analysis, a statistical method 371 to study whether the results we found in our observational analyses were likely to be 372 causal. Our analysis also has limitations. First, the EPIC-CVD and UKB studies had a 373 different study design (case-cohort versus cohort study). To take this into account, we 374 implemented Cox-regression with Prentice-weighting for EPIC-CVD. Second, the 375 EPIC-CVD and UKB studies mainly include individuals of European ancestries (>95% 376 for UKB), which limits the generalizability to other population groups. Of note, also the 377 underlying GWAS focused on individuals of European ancestry. Consequently, more 378 data on other populations are needed. Third, although we broadly harmonized the 379 definition of menopause in EPIC-CVD and the UKB, it differed slightly between the 380 studies as we did not have data on unilateral ovariectomy in the UKB. Fourth, 381 menopausal status was missing for some women in the UKB and we estimated it based 382 on age at baseline as suggested in previously published analyses on EPIC-CVD 383 data.²⁷ However, this only affected a small proportion of study participants 384 (approximately 1% in UKB). Fifth, as age at menopause was self-reported, our 385 analyses may also be affected by non-differential misclassification, which could have 386 led to attenuation of the association towards the null. Sixth, although stroke events 387 were ascertained comprehensively, there may remain some misclassification of 388 events. However, it has been demonstrated that positive predictive values for stroke 389 events defined based on hospital or death certificates are usually high.²⁸ Furthermore, 390 although we studied several types of stroke, stroke is a heterogeneous disease with

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license. Many etiological subtypes and we were not able to study associations with more

391 392 specific types of stroke. Seventh, Mendelian Randomization analysis relies on several 393 assumptions. The first assumption is that the genetic variants are associated with the 394 exposure variable, i.e., with age at menopause. We have used genetic variants 395 published by a recent GWAS.¹¹ After harmonization, we included 166 SNPs in our 396 instrumental variable that had a sufficiently high F-statistic (i.e., >10 as suggested by 397 Staiger and Stock²⁹) for the UKB. In EPIC-CVD, the F-statistic was rather low indicating 398 weak instrument bias, which is likely due to the lower sample size and large number of SNPs included (as the R² statistic was even higher in EPIC-CVD than in the UKB). 399 400 However, as we applied a two-sample Mendelian Randomization analysis, weak 401 instrument bias acts towards the null and will therefore be conservative and we also 402 found no significant effect of genetically proxied age at menopause on any type of 403 stroke in the UKB. Moreover, the GWAS we used to define genetically proxied age at 404 menopause focused on natural age at menopause. Therefore, our Mendelian 405 Randomization study only tests for a causal association of age at natural menopause 406 with stroke risk, while in our observational study we also included women with surgical 407 menopause. However, our observational subgroup analyses showed no statistically significant difference in effect sizes between women with natural or surgical age at 408 409 menopause. The second assumption of a Mendelian Randomization analysis relies on 410 the principle that the genetic variants are not associated with confounding factors. We 411 studied this assumption by comparing the polygenic risk score created by the SNPs 412 included in our instrumental variable across several potential confounding factors and 413 could not exclude an association between the polygenic risk score and hypertension 414 and ever use of HRT. However, when we adjusted the Mendelian Randomization 415 analysis for all phenotypes related to cardiovascular risk, the association remained 416 nonsignificant. The third assumption of a Mendelian Randomization analysis is that the

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
effect of the genetic variants on the outcome only goes through the exposure variable.
To investigate this assumption, we (1) conducted a Mendelian Randomization analysis
using MR-Egger, which yielded no significant intercepts, suggesting no evidence of
directional pleiotropy, and (2) implemented MR-PRESSO, which resulted in no
pleiotropic SNPs that should be excluded from the analysis.

422 **Comparison to previous observational studies**

423 The results from our observational analysis on risk of total stroke are comparable to previous findings from individual studies including the Korean Heart Study.³⁰ the China 424 Kadoorie Biobank,³¹ and the Nurses' Health Study³². The InterLACE consortium meta-425 426 analyzed data from over 300,000 women, whereby a large proportion of these data 427 (61%) were from the UKB, leading to an overlap with our study sample.⁹ In analyses 428 excluding data from the UKB, they also found an increased risk of developing stroke for women with younger age at menopause.⁹ Similarly, earlier age at menopause was 429 430 associated with higher risk of ischemic stroke in the Korean Heart Study³⁰ and 431 Framingham Study.³³ A study in textile workers from China did not confirm this 432 association.³⁴ However, in the InterLACE consortium, early menopause was related to higher risk of ischemic stroke, although these data included UKB as well.⁹ In our 433 434 analysis, earlier menopause was also associated with a higher risk of hemorrhagic stroke. In contrast, two previous studies^{30,34} reported no significant association 435 436 between age at menopause and risk of hemorrhagic stroke. This discrepancy is most likely due to limited statistical power, as within the InterLACE consortium, again 437 438 including UKB, risk of hemorrhagic stroke was higher in women with earlier 439 menopause.⁹ Finally, in our meta-analysis we found no significant relationship between age at menopause and risk of subarachnoid hemorrhage, unlike an investigation in the 440 441 Nurses' Health Study that reported a higher risk of aneurysmal subarachnoid hemorrhage for women with early menopause.³⁵ Of note, our observational analysis in 442

the UKB also found women with earlier age at menopause to be at higher risk of subarachnoid hemorrhage. However, after meta-analyzing data from the UKB with EPIC-CVD, the pooled hazard ratios were no longer statistically significant. This could probably be due to limited statistical power in EPIC-CVD as already mentioned above.

447

Mendelian Randomization analysis

448 Our Mendelian Randomization analysis did not provide evidence that the associations found in observational analyses are likely to be causal. This finding is in line with a 449 450 previous study on the relationship between reproductive aging and risk of coronary 451 heart disease, which also found that genetically proxied reproductive aging had no causal effect on risk of coronary heart disease.¹⁰ Furthermore, a Mendelian 452 453 Randomization analysis relying on publicly available GWAS results reported no 454 significant causal relationship between genetically proxied age at natural menopause and risk of coronary artery disease or stroke.¹¹ Similarly, a recently published 455 456 Mendelian Randomization study, using fewer genetic variants, also reported that there 457 is likely to be no causal link between age at natural menopause and risk of ischemic 458 stroke.¹² It is, therefore, likely that residual confounding is present in the observational 459 analysis even though most observational studies controlled for potential confounding 460 factors by adjusting for a set of stroke-related risk factors and female-specific factors. 461 Identifying such confounding factors could help to better understand the development 462 and progression of cardiovascular disease in women and might provide clues for 463 previously unknown factors associated with menopause as well as stroke.

464 Implications of the findings

Although our study did not find evidence of a potential causal relationship between age
at menopause and risk of stroke, age at menopause may still be an important marker
for cardiovascular disease in women as demonstrated in our observational analysis.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 468 Apparently, earlier age at menopause does not per sector and the perpendicular to the preprint in perpetuity.

469 impact on the risk of developing stroke that may be determined by one or more 470 confounding factors. This seems to hold for various types of stroke including both 471 ischemic and hemorrhagic stroke. While there was a consistent association between 472 earlier age at menopause and higher risk of intracerebral hemorrhage in both studies 473 included in our meta-analysis, the relationship with higher risk of subarachnoid 474 hemorrhage was only statistically significant in the UKB. As we were not able to 475 account for the unknown factors driving the observational results in our analysis, further 476 investigations are warranted. Several factors have been hypothesized to be 477 responsible for the increased cardiovascular risk after menopause. One frequently 478 discussed factor that has been speculated to have a cardioprotective effect in premenopausal women is estrogen.³⁶ However, it has been shown that the association 479 480 between estradiol and risk of myocardial infarction attenuated upon adjustment of age and other cardiovascular risk factors.³⁷ Furthermore, when studying causal relations of 481 482 age at menopause with different types of outcomes, associations appear to be 483 specifically confounded when assessing cardiovascular risk as, for instance, 484 genetically proxied age at menopause was causally related to risk of osteoporosis, fractures, and lung cancer.¹² Understanding the mechanisms that lead to the 485 486 observational relationship between earlier menopause and higher risk of stroke may 487 help close an important knowledge gap that could enable us to better understand sex-488 differences in the development of stroke.

489 **Conclusion**

490 Earlier age at menopause is associated with, but not causally related to, the risk of491 stroke.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Acknowledgements 492

493 This research has been conducted using the UKB Resource (Application Number 494 29916). We are extremely grateful to all participants in UKB. This work was supported 495 by core funding from the British Heart Foundation (RG/13/13/30194; RG/18/13/33946) 496 and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) [*]. EPIC-CVD 497 was funded by the European Research Council (268834), the European Commission 498 Framework Programme 7 (HEALTH-F2-2012-279233) and Novartis. We thank all 499 EPIC participants and staff for their contribution to the study, the laboratory teams at 500 the Medical Research Council Epidemiology Unit for sample management and 501 Cambridge Genomic Services for genotyping, Sarah Spackman for data management, 502 and the team at the EPIC-CVD Coordinating Centre for study coordination and 503 administration. *The views expressed are those of the author(s) and not necessarily 504 those of the NIHR or the Department of Health and Social Care. The GWAS array was 505 funded by the European Commission Framework Programme 7 (HEALTH-F2-2012-506 279233). Exomechip genotyping projects were funded by Pfizer and Merck. Where 507 authors are identified as personnel of the International Agency for Research on Cancer 508 /World Health Organization, the authors alone are responsible for the views expressed 509 in this article and they do not necessarily represent the decisions, policy or views of 510 the International Agency for Research on Cancer / World Health Organization. 511 Furthermore, we thank Bas B L Penning de Vries for valuable advice on the multiple 512 imputation analysis.

Sources of Funding 513

514 This work was funded by the Austrian Science Fund (T 1253).

515 **Disclosures**

- 516 None.
- 517 Supplemental Material
- 518 Supplemental Methods
- 519 eTables 1-6
- 520 eFigures 1-5

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

521 **References**

- 522 1. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, Abbasi-
- 523 Kangevari M, Abbastabar H, Abd-Allah F, Abdelalim A, et al. Global burden of
- 524 369 diseases and injuries in 204 countries and territories, 1990–2019: a
- 525 systematic analysis for the Global Burden of Disease Study 2019. *Lancet*.
- 526 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- 527 2. Institute for Health Metrics and Evaluation. GBD Compare Data Visualization.
- 528 Seattle, WA: IHME, University of Washington web site.
- 529 https://vizhub.healthdata.org/gbd-compare/. Accessed July 21, 2022.
- 530 3. Vyas MV, Silver FL, Austin PC, Yu AYX, Pequeno P, Fang J, Laupacis A, Kapral
- 531 MK. Stroke Incidence by Sex Across the Lifespan. *Stroke*. 2021;52:447–451. doi:
- 532 10.1161/strokeaha.120.032898.
- 533 4. Rexrode KM, Madsen TE, Yu AYX, Carcel C, Lichtman JH, Miller EC. The
- 534 Impact of Sex and Gender on Stroke. *Circ Res.* 2022;130:512–528. doi:
- 535 10.1161/CIRCRESAHA.121.319915.
- 536 5. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O,
- 537 Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, et al. Pregnancy and
- 538 Reproductive Risk Factors for Cardiovascular Disease in Women. *Circ Res.*
- 539 2022;130:652–672. doi: 10.1161/CIRCRESAHA.121.319895.
- 540 6. Nelson HD. Menopause. *Lancet*. 2008;371:760–770. doi: 10.1016/S0140-
- 541 6736(08)60346-3.
- 542 7. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD,
- 543 Limacher MC, Manson JE, Stefanick ML, Allison MA. Menopause Transition and
- 544 Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A
- 545 Scientific Statement From the American Heart Association. *Circulation*.
- 546 2020;142:e506-e532. doi: 10.1161/CIR.000000000000912.

- 8. Peters SA, Woodward M. Women's reproductive factors and incident
- 548 cardiovascular disease in the UK Biobank. *Heart.* 2018;104:1069–1075. doi:
- 549 10.1136/heartjnl-2017-312289.
- 550 9. Zhu D, Chung H-F, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ,
- 551 Kuh D, Hardy R, Avis NE, et al. Age at natural menopause and risk of incident
- 552 cardiovascular disease: a pooled analysis of individual patient data. *The Lancet*

553 *Public Health.* 2019;4:e553-e564. doi: 10.1016/S2468-2667(19)30155-0.

- 10. Dam V, Onland-Moret NC, Burgess S, Chirlaque M-D, Peters SAE, Schuit E,
- 555 Tikk K, Weiderpass E, Oliver-Williams C, Wood AM, et al. Genetically
- 556 Determined Reproductive Aging and Coronary Heart Disease: A Bidirectional 2-
- 557 sample Mendelian Randomization. J Clin Endocrinol Metab. 2022;107:e2952-
- 558 e2961. doi: 10.1210/clinem/dgac171.
- 11. Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, Azad A, Thompson
- 560 DJ, Knoblochova L, Abe H, Tarry-Adkins JL, et al. Genetic insights into biological
- 561 mechanisms governing human ovarian ageing. *Nature*. 2021;596:393–397. doi:
- 562 10.1038/s41586-021-03779-7.
- 563 12. Lankester J, Li J, Salfati ELI, Stefanick ML, Chan KHK, Liu S, Crandall CJ,
- 564 Clarke SL, Assimes TL. Genetic evidence for causal relationships between age
- at natural menopause and the risk of ageing-associated adverse health

566 outcomes. Int J Epidemiol. 2022. doi: 10.1093/ije/dyac215.

- 13. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J,
- 568 Green J, Matthews P, Pell J, et al. UK Biobank: Current status and what it means
- 569 for epidemiology. *Health Policy and Technology*. 2012;1:123–126. doi:
- 570 10.1016/j.hlpt.2012.07.003.
- 571 14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
- 572 P, Green J, Landray M, et al. UK biobank: an open access resource for

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license identifying the causes of a Wide range of complex diseases of middle and old

573

574 age. *PLoS Med*. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.

- 575 15. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondière UR,
- 576 Hémon B, Casagrande C, Vignat J, et al. European Prospective Investigation
- 577 into Cancer and Nutrition (EPIC): study populations and data collection. *Public*
- 578 *Health Nutr.* 2002;5:1113–1124. doi: 10.1079/PHN2002394.
- 16. Danesh J, Saracci R, Berglund G, Feskens E, Overvad K, Panico S, Thompson
- 580 S, Fournier A, Clavel-Chapelon F, Canonico M, et al. EPIC-Heart: the
- 581 cardiovascular component of a prospective study of nutritional, lifestyle and
- 582 biological factors in 520,000 middle-aged participants from 10 European
- 583 countries. *Eur J Epidemiol*. 2007;22:129–141. doi: 10.1007/s10654-006-9096-8.
- 17. Langenberg C, Sharp S, Forouhi NG, Franks PW, Schulze MB, Kerrison N,
- 585 Ekelund U, Barroso I, Panico S, Tormo MJ, et al. Design and cohort description
- 586 of the InterAct Project: an examination of the interaction of genetic and lifestyle
- 587 factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia*.
- 588 2011;54:2272–2282. doi: 10.1007/s00125-011-2182-9.
- 589 18. Zheng J-S, Luan J, Sofianopoulou E, Imamura F, Stewart ID, Day FR, Pietzner
- 590 M, Wheeler E, Lotta LA, Gundersen TE, et al. Plasma Vitamin C and Type 2
- 591 Diabetes: Genome-Wide Association Study and Mendelian Randomization
- 592 Analysis in European Populations. *Diabetes Care*. 2021;44:98–106. doi:
- 593 10.2337/dc20-1328.
- 594 19. Collins R. What makes UK Biobank special? *Lancet*. 2012;379:1173–1174. doi:
 595 10.1016/S0140-6736(12)60404-8.
- 596 20. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
- 597 Vukcevic D, Delaneau O, O'Connell J, et al. Genome-wide genetic data on
- 598 ~500,000 UK Biobank participants. *bioRxiv*. 2017. doi: 10.1101/166298.

- 599 21. Onland-Moret NC, van der A DL, van der Schouw YT, Buschers W, Elias SG,
- 600 van Gils CH, Koerselman J, Roest M, Grobbee DE, Peeters PHM. Analysis of
- 601 case-cohort data: a comparison of different methods. *J Clin Epidemiol*.
- 602 2007;60:350–355. doi: 10.1016/j.jclinepi.2006.06.022.
- 603 22. Firth D. Quasi-variances. *Biometrika*. 2004;91:65–80. doi:
- 604 10.1093/biomet/91.1.65.
- 605 23. White IR. Multivariate Random-effects Meta-analysis. Stata J. 2009;9:40–56. doi:
- 606 10.1177/1536867X0900900103.
- 607 24. Privé F, Luu K, Blum MGB, McGrath JJ, Vilhjálmsson BJ. Efficient toolkit
- 608 implementing best practices for principal component analysis of population
- 609 genetic data. *Bioinformatics*. 2020;36:4449–4457. doi:
- 610 10.1093/bioinformatics/btaa520.
- 611 25. Yavorska OO, Burgess S. MendelianRandomization: an R package for
- 612 performing Mendelian randomization analyses using summarized data. Int J

613 *Epidemiol.* 2017;46:1734–1739. doi: 10.1093/ije/dyx034.

- 614 26. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
- 615 pleiotropy in causal relationships inferred from Mendelian randomization
- between complex traits and diseases. *Nat Genet*. 2018;50:693–698. doi:
- 617 10.1038/s41588-018-0099-7.
- 618 27. Dam V, van der Schouw YT, Onland-Moret NC, Groenwold RHH, Peters SAE,
- Burgess S, Wood AM, Chirlaque M-D, Moons KGM, Oliver-Williams C, et al.
- 620 Association of menopausal characteristics and risk of coronary heart disease: a
- 621 pan-European case-cohort analysis. *Int J Epidemiol*. 2019;48:1275–1285. doi:
- 622 10.1093/ije/dyz016.
- 623 28. Woodfield R, Grant I, Sudlow CLM. Accuracy of Electronic Health Record Data
- 624 for Identifying Stroke Cases in Large-Scale Epidemiological Studies: A

- 625 Systematic Review from the UK Biobank Stroke Outcomes Group. *PLoS One*.
- 626 2015;10:e0140533. doi: 10.1371/journal.pone.0140533.
- 627 29. Staiger D, Stock JH. Instrumental Variables Regression with Weak Instruments.
- 628 Econometrica. 1997;65:557. doi: 10.2307/2171753.
- 629 30. Jung KJ, Kim M-R, Yun YD, Kim HC, Jee SH. Duration of ovarian hormone
- 630 exposure and atherosclerotic cardiovascular disease in Korean women: the
- 631 Korean Heart Study. *Menopause*. 2016;23:60–66. doi:
- 632 10.1097/GME.00000000000489.
- 633 31. Yang L, Lin L, Kartsonaki C, Guo Y, Chen Y, Bian Z, Xie K, Jin D, Li L, Lv J, et
- al. Menopause Characteristics, Total Reproductive Years, and Risk of
- 635 Cardiovascular Disease Among Chinese Women. *Circ Cardiovasc Qual*
- 636 *Outcomes*. 2017;10. doi: 10.1161/CIRCOUTCOMES.117.004235.
- 637 32. Ley SH, Li Y, Tobias DK, Manson JE, Rosner B, Hu FB, Rexrode KM. Duration
- 638 of Reproductive Life Span, Age at Menarche, and Age at Menopause Are
- 639 Associated With Risk of Cardiovascular Disease in Women. J Am Heart Assoc.
- 640 2017;6. doi: 10.1161/JAHA.117.006713.
- 33. Lisabeth LD, Beiser AS, Brown DL, Murabito JM, Kelly-Hayes M, Wolf PA. Age
- at natural menopause and risk of ischemic stroke: the Framingham heart study.
- 643 *Stroke*. 2009;40:1044–1049. doi: 10.1161/STROKEAHA.108.542993.
- 644 34. Gallagher LG, Davis LB, Ray RM, Psaty BM, Gao DL, Checkoway H, Thomas
- 645 DB. Reproductive history and mortality from cardiovascular disease among
- 646 women textile workers in Shanghai, China. *Int J Epidemiol*. 2011;40:1510–1518.
- 647 doi: 10.1093/ije/dyr134.
- 648 35. Lai PMR, Jimenez M, Du R, Rexrode K. Association of Reproductive Life Span
- and Age at Menopause With the Risk of Aneurysmal Subarachnoid Hemorrhage.
- 650 *Neurology*. 2022;98:e2005-e2012. doi: 10.1212/WNL.000000000200222.

- 651 36. lorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The
- 652 protective role of estrogen and estrogen receptors in cardiovascular disease and
- the controversial use of estrogen therapy. *Biol Sex Differ*. 2017;8:33. doi:
- 654 10.1186/s13293-017-0152-8.
- 655 37. Peters SAE, Woodward M. Oestradiol and the risk of myocardial infarction in
- 656 women: a cohort study of UK Biobank participants. Int J Epidemiol.
- 657 2021;50:1241–1249. doi: 10.1093/ije/dyaa284.
- 658 38. Geistanger A, Arends S, Berding C, Hoshino T, Jeppsson J-O, Little R, Siebelder
- 659 C, Weykamp C. Statistical methods for monitoring the relationship between the
- 660 IFCC reference measurement procedure for hemoglobin A1c and the designated
- 661 comparison methods in the United States, Japan, and Sweden. *Clin Chem.*
- 662 2008;54:1379–1385. doi: 10.1373/clinchem.2008.103556.
- 663 39. Peters T, Brage S, Westgate K, Franks PW, Gradmark A, Tormo Diaz MJ,
- 664 Huerta JM, Bendinelli B, Vigl M, Boeing H, et al. Validity of a short questionnaire
- to assess physical activity in 10 European countries. *Eur J Epidemiol*.
- 666 2012;27:15–25. doi: 10.1007/s10654-011-9625-y.
- 40. Guidelines for data processing analysis of the International Physical Activity
- 668 Questionnaire (IPAQ) Short and long forms.
- 41. White IR, Royston P. Imputing missing covariate values for the Cox model. *Stat Med.* 2009;28:1982–1998. doi: 10.1002/sim.3618.
- 42. Burgess S, White IR, Resche-Rigon M, Wood AM. Combining multiple imputation
- and meta-analysis with individual participant data. Stat Med. 2013;32:4499–
- 673 4514. doi: 10.1002/sim.5844.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

675 Figure legends

Figure 1. Participant flow chart. *Excluded because follow-up for stroke was unavailable in French centers. [†]Excluded because important covariates were not measured in Norwegian centers. [‡]Excluded because of administrative constraints. [§]Of these, 5,292 belonged to the sub-cohort and 2,591 were stroke cases outside the subcohort. ^{II}Of these, 4,127 belonged to the sub-cohort and 1,616 were stroke cases outside the sub-cohort.

682 Figure 2. Association of age at menopause and risk of stroke. Hazard ratios are 683 adjusted for age, smoking status, body mass index, glycated hemoglobin, total 684 cholesterol, hypertension, ever use of hormone replacement therapy, and age at 685 menarche. Dots indicate point estimates and whiskers 95% confidence intervals for 686 the categories <40, 40 to <45, 45 to <50, 50 to <55, and \geq 55 years of age at 687 menopause. Age at menopause from 50 to <55 years was used as reference category. 688 Restricted cubic splines are based on three knots at 45, 50, and 55 years of age at 689 menopause using an age of 50 years at menopause as reference.

Figure 3. Mendelian Randomization analysis on genetically proxied age at
menopause and risk of stroke. Hazard ratios are per five years younger genetically
proxied age at menopause. Abbreviations: CI, confidence interval; IVW, inverse
variance weighted.

Tables 694

695 Table 1. Baseline characteristics.

	Overall (n=201,653*)		E (EPIC-CVD n=5,292*)	UK Biobank (n=196,361)		
Characteristic	Total No.	Mean ± SD, median [IQR], No. (%†)	Total No.	Mean ± SD, median [IQR], No. (% [†])	Total No.	Mean ± SD, median [IQR], No. (% [†])	
Stroke risk factors							
Age, years	201,653	58.9 ± 5.8	5,292	58.0 ± 6.4	196,361	59.9 ± 5.7	
Systolic BP, mmHg	189,007	137.1 ± 19.2	4,296	135.7 ± 20.0	184,711	138.4 ± 19.2	
Diastolic BP, mmHg	189,009	81.6 ± 9.9	4,296	82.0 ± 10.4	184,713	81.2 ± 9.9	
Hypertension	200,858	103,069 (51.3%)	5,245	2,362 (45.0%)	195,613	100,707 (51.5%)	
Body mass index, kg/m ²	200,628	26.8 ± 5.1	5,258	26.4 ± 4.6	195,370	27.3 ± 5.1	
Education	197,661		5,182		192,479		
Low		43,350 (21.9%)		2,026 (39.1%)		41,324 (21.5%)	
Medium		48,764 (24.7%)		615 (11.9%)		48,149 (25.0%)	
High		104,994 (53.1%)		1,988 (38.4%)		103,006 (53.5%)	
Smoking status	200,560		5,254		195,306		
Never		116,329 (58.0%)		3,071 (58.5%)		113,258 (58.0%)	
Ex		66,778 (33.3%)		1,092 (20.8%)		65,686 (33.6%)	
Current		17,453 (8.7%)		1,091 (20.8%)		16,362 (8.4%)	
Total cholesterol, mmol/L	188,029	6.2 ± 1.1	5,049	6.3 ± 1.2	182,980	6.0 ± 1.1	
HDL cholesterol, mmol/L	171,617	1.6 ± 0.4	5,049	1.6 ± 0.4	166,568	1.6 ± 0.4	
Triglycerides, mmol/L	187,916	1.4 [1.0, 2.0]	5,046	1.2 [0.8, 1.6]	182,870	1.4 [1.0, 2.0]	
HbA1c, %	186,905	5.6 ± 0.5	5,194	5.6 ± 0.7	181,711	5.5 ± 0.5	
Female-specific factors							
Age at menopause, years	189,095	47.8 ± 6.2	4,754	47.3 ± 6.4	184,341	48.4 ± 6.2	
Surgical menopause	201,653	45,193 (22.4%)	5,292	1,235 (23.3%)	196,361	43,958 (22.4%)	
Ever use of HRT	200,206	100,203 (50.0%)	4,722	1,733 (36.7%)	195,484	98,470 (50.4%)	
Ever use of OCP	200,736	155,303 (77.4%)	5,206	2,329 (44.7%)	195,530	152,974 (78.2%)	
Age at menarche, years	195,496	13.2 ± 1.6	5,156	13.4 ± 1.6	190,340	12.9 ± 1.6	

696

*Only participants of the EPIC-CVD sub-cohort were included in this table. †The denominator for all 697 percentages was the number of postmenopausal women without missing values in the respective 698 variable. Abbreviations: BP, blood pressure; OCP, oral contraceptive pill; HbA1c, glycated hemoglobin; 699 HRT, hormone replacement therapy; IQR, interquartile range; SD, standard deviation.

700

Table 2. Association between age at menopause and risk of stroke in the EPIC-

701 CVD and UK Biobank studies (n=204,244).

Outcome/Age at	No. of	Model 1		Model 2		Model 3		
menopause (years)	cases	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend	
Stroke								
<40	700	1.54 (1.36-1.75)		1.41 (1.27-1.58)		1.42 (1.28-1.56)		
40 to<45	891	1.31 (1.21-1.41)		1.24 (1.15-1.33)		1.23 (1.14-1.33)		
45 to <50	1,742	1.13 (1.05-1.23)	<0.001	1.10 (1.02-1.19)	<0.001	1.10 (1.02-1.19)	<0.001	
50 to <55	2,623	1.00 (0.96-1.04)		1.00 (0.96-1.04)		1.00 (0.96-1.04)		
≥55	814	0.96 (0.83-1.10)		0.95 (0.83-1.10)		0.96 (0.84-1.10)		
per 5 years younger	6,770	1.12 (1.10-1.15)		1.10 (1.07-1.12)		1.09 (1.07-1.12)		
Ischemic stroke								
<40	534	1.59 (1.41-1.80)		1.43 (1.28-1.58)		1.43 (1.30-1.57)		
40 to<45	653	1.29 (1.15-1.45)		1.21 (1.07-1.36)		1.20 (1.07-1.36)		
45 to <50	1,350	1.16 (1.08-1.24)	<0.001	1.12 (1.05-1.20)	<0.001	1.12 (1.05-1.20)	<0.001	
50 to <55	1,995	1.00 (0.95-1.05)		1.00 (0.95-1.05)		1.00 (0.94-1.06)		
≥55	623	0.95 (0.79-1.16)		0.94 (0.77-1.15)		0.95 (0.78-1.16)		
per 5 years younger	5,155	1.12 (1.10-1.15)		1.09 (1.07-1.12)		1.09 (1.06-1.13)		
Hemorrhagic stroke								
<40	166	1.37 (1.03-1.81)		1.32 (0.97-1.79)		1.33 (0.99-1.80)		
40 to<45	238	1.32 (1.03-1.69)		1.29 (1.00-1.67)		1.30 (1.01-1.68)		
45 to <50	392	1.08 (0.92-1.25)	0.007	1.06 (0.91-1.22)	0.036	1.06 (0.91-1.23)	0.022	
50 to <55	628	1.00 (0.93-1.08)		1.00 (0.92-1.09)		1.00 (0.92-1.08)		
≥55	191	0.97 (0.83-1.13)		1.00 (0.85-1.17)		0.99 (0.85-1.16)		
per 5 years younger	1,615	1.11 (1.06-1.17)		1.09 (1.03-1.16)		1.10 (1.04-1.16)		
Intracerebral hemorrh	nage							
<40	102	1.52 (1.25-1.86)		1.50 (1.23-1.84)		1.53 (1.25-1.87)		
40 to<45	145	1.38 (1.16-1.65)		1.37 (1.15-1.64)		1.38 (1.16-1.65)		
45 to <50	224	1.02 (0.88-1.17)	<0.001	1.02 (0.88-1.17)	<0.001	1.02 (0.89-1.17)	<0.001	
50 to <55	394	1.00 (0.90-1.11)		1.00 (0.90-1.12)		1.00 (0.90-1.12)		
≥55	111	0.84 (0.69-1.03)		0.85 (0.69-1.04)		0.85 (0.69-1.04)		
per 5 years younger	976	1.15 (1.09-1.21)		1.14 (1.08-1.20)		1.14 (1.08-1.20)		
Subarachnoid hemor	rhage							
<40	64	1.19 (0.71-2.00)		1.08 (0.59-1.98)		1.10 (0.62-1.96)		
40 to<45	93	1.20 (0.68-2.11)		1.15 (0.63-2.08)		1.15 (0.64-2.06)		
45 to <50	168	1.17 (0.94-1.45)	0.615	1.11 (0.94-1.31)	0.952	1.11 (0.93-1.32)	0.923	
50 to <55	234	1.00 (0.81-1.24)		1.00 (0.81-1.24)		1.00 (0.81-1.24)		
≥55	80	1.26 (0.96-1.65)		1.33 (0.96-1.84)		1.33 (0.96-1.83)		
per 5 years younger	639	1.03 (0.88-1.20)		1.00 (0.82-1.21)		1.00 (0.84-1.20)		

703

702 Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone 704 replacement therapy and age at menarche. Confidence intervals for each age at menopause category 705 are presented using quasi variances in order to enhance the comparison between individual categories. 706 Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for 707 linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio.

Figures 708

Figure 1. Participant flow chart. 709



- *Excluded because follow-up for stroke was unavailable in French centers. †Excluded because important covariates were not measured in Norwegian centers.
- 712 [‡]Excluded because of administrative constraints. [§]Of these, 5,292 belonged to the sub-cohort and 2,591 were stroke cases outside the sub-cohort. ^{II}Of these,
- 713 4,127 belonged to the sub-cohort and 1,616 were stroke cases outside the sub-cohort.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 Figure 2. Association of age at menopause and risk of stroke.

714



717 Hazard ratios are adjusted for age, smoking status, body mass index, glycated hemoglobin, total 718 cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. Dots 719 indicate point estimates and whiskers 95% confidence intervals for the categories <40, 40 to <45, 45 to 720 <50, 50 to <55, and ≥55 years of age at menopause. Age at menopause from 50 to <55 years was used 721 as reference category. Restricted cubic splines are based on three knots at 45, 50, and 55 years of age 722 at menopause using an age of 50 years at menopause as reference.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 Figure 3. Mendelian Randomization analysis on genetically proxied age at

723

724 menopause and risk of stroke.

Outcome/Method				н	azard ratio (95% CI)	P-value
Stroke						
IVW					0.95 (0.82-1.09)	0.445
Simple median			_ +		1.00 (0.79-1.25)	0.982
Weighted median			e		0.98 (0.78-1.25)	0.893
MR-Egger (P _{Intercept} =0.816)					0.91 (0.66-1.27)	0.589
Ischemic stroke						
IVW					0.98 (0.83-1.16)	0.805
Simple median			•		0.99 (0.77-1.28)	0.952
Weighted median			_		1.06 (0.81-1.39)	0.681
MR-Egger (P _{Intercept} =0.862)		_			1.01 (0.69-1.48)	0.960
Hemorrhagic stroke						
IVW		_	∎		0.85 (0.65-1.11)	0.230
Simple median					0.98 (0.64-1.52)	0.940
Weighted median					0.86 (0.55-1.34)	0.508
MR-Egger (P _{Intercept} =0.432)					0.68 (0.37-1.26)	0.219
Intracerebral hemorrhage						
IVW		_			0.92 (0.65-1.29)	0.617
Simple median			•	_	1.00 (0.57-1.76)	0.990
Weighted median					1.11 (0.62–2.00)	0.715
MR-Egger (P _{Intercept} =0.880)			-	\rightarrow	0.97 (0.44-2.15)	0.935
Subarachnoid hemorrhage						
IVW			•		0.75 (0.50-1.14)	0.184
Simple median					0.80 (0.41-1.55)	0.503
Weighted median	-				0.64 (0.33-1.24)	0.187
MR-Egger (P _{Intercept} =0.161)	←				0.40 (0.15-1.06)	0.066
	0.25	0.50	1.0	2.0		



Hazard ratios are per five years younger genetically proxied age at menopause. Abbreviations: CI, confidence interval; IVW, inverse variance weighted.

, 728	nedRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . SUPPLEMENTAL MATERIAL
729	Age at menopause and the risk of stroke: Observational and Mendelian
730	Randomization analysis in 204,244 postmenopausal women
731	Tschiderer et al.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 Supplemental Methods

732

Assessment and definition of additional variables 733

734 In the UK Biobank, hypertension was defined as self-reported intake of 735 antihypertensive medication or as having a systolic blood pressure >140 mmHg or a 736 diastolic blood pressure >90 mmHg taking into account the average of two blood 737 pressure measures taken a few moments apart. In EPIC-CVD, hypertension was 738 defined as having a systolic blood pressure >140 mmHg, a diastolic blood pressure 739 >90 mmHg, a self-reported history of hypertension, or as self-reported intake of 740 antihypertensive medication. In both studies, body mass index was calculated by 741 dividing weight in kg by height in m². In EPIC-CVD, low socioeconomic status was 742 defined according to education, whereby no or primary schooling indicated low, 743 secondary schooling indicated medium, and vocational schooling or university 744 indicated high socioeconomic status. In the UK Biobank, socioeconomic status was 745 defined according to thirds of the Townsend index, whereby values ≤-3.2 indicated 746 low, >-3.2 and ≤-0.803 indicated medium, and >-0.803 indicated high socioeconomic 747 status. Smoking was divided into never, ex, and current tobacco smoking. Lipid levels, 748 including total cholesterol, high-density lipoprotein cholesterol, and triglycerides, were 749 measured in serum samples at baseline on a Roche auto-analyzer at Stichting 750 Huisartsen Laboratorium (Etten-Leur, The Netherlands) in EPIC-CVD and using a 751 Beckman Coulter AU5800 platform in UK Biobank. Erythrocyte glycated hemoglobin 752 (HbA1c) was measured using the Tosoh-G8 HPLC analyzer (Tosoh Bioscience, 753 Japan) in EPIC-CVD and with Bio-Rad Variant II Turbo analyzers in the UK Biobank. 754 In the UK Biobank, HbA1c was transformed from mmol/mol to % in using the formula [HbA1c in %] = 2.15 + 0.0915*[HbA1c in mmol/mol].³⁸ Physical activity was defined 755 according to the Cambridge physical activity index in EPIC-CVD³⁹ and according to 756

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
757 the International Physical Activity Questionnaire (IPAQ) scoring protocol (short
758 forms)⁴⁰ in the UK Biobank. In addition, ever use of hormone replacement therapy and
759 ever use of oral contraceptive pill was self-reported in both studies. Finally, age at
760 menarche was defined as age at first menstrual period, which was self-reported in
761 both studies.

762 Multiple imputation of missing values

763 We imputed missing values using multiple imputation by chained equations with 14 764 datasets and 30 iterations. We included the following variables into our imputation 765 high-density lipoprotein model: total cholesterol. cholesterol, trialycerides. 766 apolipoprotein A1, apolipoprotein B, HbA1c, ever use of oral contraceptive pill, age at 767 menarche, age at menopause, body mass index, history of diabetes mellitus, 768 hypertension, ever use of hormone replacement therapy, smoking status, age at 769 baseline, menopausal status, physical activity, type of menopause, incident stroke 770 indicator, incident ischemic stroke indicator, incident hemorrhagic stroke indicator, 771 incident intracerebral hemorrhage indicator, incident subarachnoid hemorrhage 772 indicator, the Nelson-Aalen estimator for stroke (weighted by the sampling fraction for 773 EPIC-CVD)⁴¹ for both the UK Biobank and EPIC-CVD. Additionally, we used the 774 variables systolic blood pressure, diastolic blood pressure, and Townsend index for 775 the UK Biobank and the variables center, country, and education for EPIC-CVD. In 776 case the Pearson correlation coefficient between two predictors was higher than 0.7 777 or lower than -0.7, we only used the predictor with the higher correlation coefficient 778 with the imputed variable. Furthermore, we implemented passive multiple imputation 779 for the variable representing categories of age at menopause. For the meta-analysis we used within-study multiple imputation as suggested by Burgess et al.⁴², i.e., we 780

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 multiply imputed missing values in each study, combined the results by Rubin's rule,

and applied random-effects meta-analysis to combine the individual study results.

783 Selection of SNPs

- The selection process of SNPs included in the Mendelian Randomization analysis is
- 785 demonstrated in **eFigure 3**. A detailed list of SNPs included is provided in **eTable 1**.
- 786 Of the 290 SNPs identified by the GWAS,¹¹ we excluded (1) 63 SNPs because data
- 787 were not available in EPIC-CVD; (2) 16 SNPs because they were palindromic and had
- an allele frequency between 0.3 and 0.7 obtained from either the summary data from
- the GWAS, within UK Biobank, or EPIC-CVD; and (3) 45 SNPs because they were
- rare with a minor allele frequency <0.1. Finally, we included 166 SNPs into our
- instrumental variable to genetically proxy age at menopause. Additionally, we checked
- whether the genetic variants were reported on the correct allele and harmonized the
- 793 data accordingly.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 It is made available under a CC-BY 4.0 International license .
 Supplemental Tables

794

795 eTable 1. Selection of SNPs.

SNPs obtained from	SNPs in ma	SNPs in sensitivity analysis after exclusion, because		
GWAS	data not available in EPIC-CVD	palindromic and allele frequency between 0.3 and 0.7	minor allele frequency <0.1	minor allele frequency <0.01
rs200448	rs200448	rs200448	rs200448	rs200448
rs9438982	rs9438982	rs9438982	rs9438982	rs9438982
rs12046563	rs12046563	rs12046563	rs12046563	rs12046563
rs57259875	rs57259875	rs57259875	rs57259875	rs57259875
rs112869704	rs112869704	rs112869704	rs112869704	rs112869704
rs12133213	-	-	-	-
rs11102802	rs11102802	rs11102802	rs11102802	rs11102802
rs72708144	rs72708144	rs72708144	-	rs72708144
rs2736609	rs2736609	rs2736609	rs2736609	rs2736609
rs41272475	rs41272475	rs41272475	-	-
rs371125724	-	-	-	-
rs11582336	rs11582336	rs11582336	rs11582336	rs11582336
rs1044595	rs1044595	rs1044595	rs1044595	rs1044595
rs7515939	rs7515939	-	-	-
rs4653680	-	-	-	-
rs7414807	rs7414807	rs7414807	rs7414807	rs7414807
rs1635506	rs1635506	rs1635506	rs1635506	rs1635506
rs72755295	rs72755295	rs72755295	-	rs72755295
rs851797	rs851797	rs851797	rs851797	rs851797
rs7539755	rs7539755	rs7539755	rs7539755	rs7539755
rs7779	rs7779	rs7779	-	rs7779
rs112866529	rs112866529	rs112866529	rs112866529	rs112866529
rs780088	rs780088	rs780088	rs780088	rs780088
rs12053063	rs12053063	rs12053063	rs12053063	rs12053063
rs10198789	rs10198789	rs10198789	rs10198789	rs10198789
rs67600408	rs67600408	rs67600408	_	rs67600408
rs17425341	rs17425341	rs17425341	rs17425341	rs17425341
rs76928871	rs76928871	rs76928871	rs76928871	rs76928871
rs2293269	rs2293269	_	_	-
rs199638788	_	_	_	_
rs62156756	rs62156756	rs62156756	rs62156756	rs62156756
rs4852777	rs4852777	_	_	-
rs67893326	rs67893326	rs67893326	rs67893326	rs67893326
rs59854799	_	_	_	-
rs6727266	rs6727266	rs6727266	rs6727266	rs6727266
rs72827480	rs72827480	rs72827480	rs72827480	rs72827480
rs6430545	rs6430545	_	_	-
rs16830019	rs16830019	rs16830019	rs16830019	rs16830019
rs4668354	rs4668354	_	_	_
rs201478184	_	_	_	_
rs6719012	rs6719012	rs6719012	rs6719012	rs6719012
rs4972504	rs4972504	rs4972504	rs4972504	rs4972504
rs72934556	rs72934556	rs72934556	rs72934556	rs72934556
rs540836853	-	_	_	-
rs6736096	rs6736096	rs6736096	rs6736096	rs6736096
rs7558434	rs7558434	rs7558434	rs7558434	rs7558434
rs62193239	rs62193239	rs62193239	rs62193239	rs62193239
rs606920	rs606920	rs606920	rs606920	rs606920
rs12636454	rs12636454	rs12636454	rs12636454	rs12636454
1312030434	1312030434	1312030434	1312030434	1312030434

rs62244773	rs62244773 ht is made	available under a CC-BY	4.0 International license .	_
rs12487736	rs12487736	rs12487736	rs12487736	rs12487736
rs1264191	rs1264191	rs1264191	rs1264191	rs1264191
rs3/675186	-	-	-	_
rs9968117	rc0068117	rc9968117	rc9968117	rs9968117
rc200E2EE	rc2005255	-	-	-
152003233	-	_	_	_
15/610102	-	-	-	-
154679244	154679244	154679244	rs4679244	154679244
rs6/93835	rs6/93835	rs6/93835	rs6793835	rs6793835
rs1545597	rs1545597	rs1545597	rs1545597	rs1545597
rs10154963	rs10154963	rs10154963	rs10154963	rs10154963
rs344018	rs344018	rs344018	rs344018	rs344018
rs72268838	-	-	-	-
rs10804920	rs10804920	rs10804920	rs10804920	rs10804920
rs979481644	-	-	-	-
rs13070791	rs13070791	rs13070791	rs13070791	rs13070791
rs3796624	rs3796624	rs3796624	rs3796624	rs3796624
rs2052160	rs2052160	rs2052160	rs2052160	rs2052160
rs190043078	-	-	-	-
rs6824237	rs6824237	rs6824237	rs6824237	rs6824237
rs2581458	rs2581458	rs2581458	rs2581458	rs2581458
rs76540949	-	_	_	-
rs12651246	rs12651246	rs12651246	rs12651246	rs12651246
rs7698733	-	-	-	-
rs145615497	rs145615497	rs145615497	-	rs145615497
rs6810489	rs6810489	rs6810489	rs6810489	rs6810489
rs35713108	-	-	-	-
rs112898082	rs112898082	rs112898082	rs112898082	rs112898082
rs2139178	rs2139178	rs2139178	rs2139178	rs2139178
rs9990489	rs9990489	rs9990489	rs9990489	rs9990489
rs27/1701	rs27/701	rs274701	rs274701	rs274701
rc20167012	rc80167018	rc20167012	-	rs20167018
rc62256072	rc62256072	1300107910	- rcf3256072	1300107918
rs17206501	rs17206E01	1302330073	1302330073	1302330073
1517200591	1517200591	1517200591	1517200591	1517200591
157728833	157728833	157728833	157728833	157728833
1510070308	1510070308	1510070308	101070308	1510070308
rs104//1/2	rs10477172	rs10477172	rs10477172	rs10477172
rs888694	rs888694	rs888694	-	rs888694
rs11744866	rs11744866	rs11744866	rs11744866	rs11744866
rs35813302	rs35813302	rs35813302	rs35813302	rs35813302
rs2241584	rs2241584	rs2241584	rs2241584	rs2241584
rs353478	rs353478	rs353478	rs353478	rs353478
rs76623841	rs76623841	rs76623841	-	rs76623841
rs9348724	rs9348724	rs9348724	rs9348724	rs9348724
rs72823382	rs72823382	rs72823382	rs72823382	rs72823382
rs4716056	rs4716056	rs4716056	rs4716056	rs4716056
rs9348752	rs9348752	rs9348752	-	rs9348752
rs6930435	rs6930435	rs6930435	rs6930435	rs6930435
rs3130040	rs3130040	rs3130040	-	rs3130040
rs4143333	rs4143333	rs4143333	-	rs4143333
rs2844466	rs2844466	rs2844466	rs2844466	rs2844466
rs9272211	-	-	-	-
rs9272982	-	-	-	_
rs7748483	rs7748483	rs7748483	-	rs7748483
rs9470134	-	_	_	_
rs515650	_	_	_	_
rs113967617	rs113067617	rs112067617	rs113067617	rs113967617
rs21/7220	rs21/7220	rs2147220	rc2147220	rs2147220
13214/220	152147220	152147220	152147220	152147220
150209048	150509048	150509048	150509048	150509048
15140381358	-	-	-	-
rs6/149731	-	_	-	-

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . rs61065130 rs11767307 rs11767307 rs11767307 rs11767307 rs11767307 rs1826838 rs1826838 rs1826838 rs1826838 rs1826838 rs62445870 rs62445870 rs62445870 rs62445870 rs375846854 rs10255049 rs10255049 rs10255049 rs10255049 rs10255049 rs2023778 rs2023778 rs2023778 rs2023778 rs2023778 rs2056726 rs2056726 rs2056726 rs2056726 rs2056726 rs2392836 rs2392836 rs2392836 rs2392836 rs2392836 rs4731541 rs4731541 rs112190116 rs2013 rs2013 rs2013 rs2013 rs2013 rs2061834 rs2061834 rs2061834 rs2061834 rs2061834 rs3750243 rs3750243 rs3750243 rs3750243 rs3750243 rs6473979 rs6473979 rs6473979 rs6473979 rs3735828 rs73264416 rs73264416 rs73264416 rs73264416 rs35529153 rs117431243 rs1467044 rs1467044 rs1467044 rs1467044 rs1467044 rs6470598 rs6470598 rs6470598 rs6470598 rs6470598 rs1476164 rs1476164 rs1476164 rs1476164 rs1476164 rs55873183 rs55873183 rs55873183 rs55873183 rs783562 rs783562 rs783562 rs783562 rs783562 rs4879656 rs4879656 rs4879656 rs4879656 rs4879656 rs10818873 rs10818873 rs10818873 rs10818873 rs138114862 rs10795520 rs10795520 rs10795520 rs10795520 rs10795520 rs74701710 rs74701710 rs74701710 rs74701710 rs10764106 rs10764106 rs10764106 rs10764106 rs10764106 rs10997819 rs10997819 rs10997819 rs10997819 rs10997819 rs10823203 rs10823203 rs10823203 rs10823203 rs10823203 rs1889921 rs1889921 rs1889921 rs1889921 rs1889921 rs7087644 rs7087644 rs7087644 rs7087644 rs74430332 rs74430332 rs74430332 rs74430332 rs10883451 rs10883451 rs10883451 rs10883451 rs10883451 rs7091889 rs7091889 rs7091889 rs7091889 rs7091889 rs11245450 rs11245450 rs11245450 rs11245450 rs11245450 rs728900 rs728900 rs6578283 rs6578283 rs6578283 rs6578283 rs6578283 rs7928823 rs34591978 rs11031006 rs11031006 rs11031006 rs11031006 rs11031006 rs10734411 rs10734411 rs10734411 rs10734411 rs10734411 rs10769315 rs10769315 rs10769315 rs10769315 rs10769315 rs7943302 rs7943302 rs7943302 rs7943302 rs7943302 rs10899493 rs10899493 rs10899493 rs10899493 rs10899493 rs11400191 rs60378595 rs148681796 rs148681796 rs148681796 rs148681796 rs10743271 rs2376898 rs2376898 rs2376898 rs2376898 rs2376898 rs77100210 rs77100210 rs77100210 rs77100210 rs61913600 rs61913600 rs61913600 rs61913600 rs61913600 rs10743724 rs10743724 rs10743724 rs10743724 rs10743724 rs10219645 rs2277339 rs2277339 rs2277339 rs2277339 rs2277339 rs28473132 rs7308068 rs7308068 rs7308068 rs7308068 rs7308068 rs75770066 rs75770066 rs75770066 rs75770066 rs61069255 rs61069255 rs61069255 rs61069255 rs61069255

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. rs192638119 _______ It is made available under a CC-BY 4.0 International license . _______

13192030119	—	-	-	-
rs5800506	-	-	-	-
rs6490269	rs6490269	rs6490269	rs6490269	rs6490269
rs2942371	rs2942371	rs2942371	rs2942371	rs2942371
rs73413716	rs73413716	rs73413716	-	rs73413716
rs12825762	rs12825762	rs12825762	rs12825762	rs12825762
rs35067339	_	_	_	_
rs28416520	rs28416520	rs28416520	rs28416520	rs28416520
rc7212001	rc7219001	rc7212001	rc7212001	rc7218001
rc11E7191E	rc11E7101E	rs11E7191E	-	-
15115/1815	15115/1615	15115/1815	-	-
15112/2/324	-	-	-	-
rs3/36830	rs3/36830	rs3/36830	rs3/36830	rs3/36830
rs7322160	rs7322160	rs7322160	rs7322160	rs7322160
rs78566820	rs78566820	rs78566820	-	-
rs12868295	rs12868295	rs12868295	rs12868295	rs12868295
rs112097885	-	-	-	-
rs1713426	rs1713426	rs1713426	rs1713426	rs1713426
rs12879626	rs12879626	rs12879626	rs12879626	rs12879626
rs61488898	rs61488898	rs61488898	-	rs61488898
rs45547534	rs45547534	rs45547534	_	rs45547534
rs1969713	rs1969713	rs1969713	rs1969713	rs1969713
rs112326803	rs112326803	rs112326803	_	rs112326803
rs762642	ro762642	rs762642	***762642	rs762642
15/02043	15/02043	15/02043	15/02043	15/02043
rs1986616	rs1986616	rs1986616	rs1986616	rs1986616
rs71126035	-	-	-	-
rs375453823	-	-	-	-
rs9796	rs9796	-	-	-
rs689816	rs689816	rs689816	rs689816	rs689816
rs11071756	rs11071756	rs11071756	rs11071756	rs11071756
rs8025068	rs8025068	rs8025068	rs8025068	rs8025068
rs8035724	rs8035724	rs8035724	rs8035724	rs8035724
rs376442546	-	-	-	-
rs716886	rs716886	rs716886	rs716886	rs716886
rs62025270	rs62025270	rs62025270	rs62025270	rs62025270
rs12898357	rs12898357	rs12898357	rs12898357	rs12898357
rs28652789	rs28652789	rs28652789	rs28652789	rs28652789
rs4796E00	rs4786E00	1320032703	1320032705	1320032703
134780303	154780505	-	-	-
1517680522	1517680522	1817680522	1817680522	1817680522
rs8045589	rs8045589	-	-	-
rs9673473	rs9673473	-	-	-
rs2173885	-	-	-	-
rs11642909	rs11642909	rs11642909	rs11642909	rs11642909
rs11075466	rs11075466	rs11075466	rs11075466	rs11075466
rs10521305	rs10521305	rs10521305	_	rs10521305
rs8045027	rs8045027	rs8045027	rs8045027	rs8045027
rs200293726	-	-	-	_
rs12447180	rs12447180	rs12447180	rs12447180	rs12447180
rs502258	rs502258	rs502258	rs502258	rs502258
rs62054610	_	_	_	_
rs2108839	-	_	_	_
rs5030755	rs5030755	rs5030755	rs5030755	rs5030755
rc2/0566E0	rc24856650	rc2/856650	rc2/0566E0	rc2/0566E0
1334030033	1324020029	1334030033	1334030039	1334030033
15222859	-	_	_	_
r\$5691455//	-	-	-	-
rs8073434	rs8073434	rs8073434	rs8073434	rs8073434
rs1565920	rs1565920	rs1565920	rs1565920	rs1565920
rs111637825	rs111637825	rs111637825	-	rs111637825
rs799903	-	-	-	-
rs1815198	rs1815198	rs1815198	rs1815198	rs1815198
rs1991401	rs1991401	rs1991401	rs1991401	rs1991401
rs34609096	rs34609096	rs34609096	rs34609096	rs34609096

154000141	154600141	154600141	154600141	154600141
rs142239484	rs142239484	rs142239484	-	-
rs12605881	rs12605881	-	-	-
rs11542373	rs11542373	rs11542373	rs11542373	rs11542373
rs349306	rs349306	rs349306	rs349306	rs349306
rs56225015	rs56225015	rs56225015	rs56225015	rs56225015
rs12459191	rs12459191	rs12459191	rs12459191	rs12459191
rs147068659	-	-	-	-
rs148807049	rs148807049	rs148807049	rs148807049	rs148807049
rs10406053	rs10406053	rs10406053	rs10406053	rs10406053
rs191031532	-	-	-	-
rs2359811	rs2359811	rs2359811	rs2359811	rs2359811
rs11670032	rs11670032	rs11670032	rs11670032	rs11670032
rs424223	rs424223	rs424223	rs424223	rs424223
rs7249357	rs7249357	rs7249357	rs7249357	rs7249357
rs11349039	-	-	-	-
rs10409547	-	-	-	-
rs11668344	rs11668344	rs11668344	rs11668344	rs11668344
rs117146677	rs117146677	rs117146677	-	rs117146677
rs8109672	rs8109672	rs8109672	rs8109672	rs8109672
rs12461110	rs12461110	rs12461110	rs12461110	rs12461110
rs8101859	rs8101859	rs8101859	rs8101859	rs8101859
rs394448	rs394448	_	-	-
rs6054257	rs6054257	rs6054257	rs6054257	rs6054257
rs73078112	rs73078112	rs73078112	_	rs73078112
rs236117	rs236117	rs236117	rs236117	rs236117
rs16991615	rs16991615	rs16991615	_	rs16991615
rs148563363	rs148563363	rs148563363	_	_
rs746748	rs746748	rs746748	_	rs746748
rs58065489	rs58065489	rs58065489	rs58065489	rs58065489
rs11699793	rs11699793	rs11699793	rs11699793	rs11699793
rs483508	rs483508	rs483508	rs483508	rs483508
rs80047570	_	_	_	_
rs7266248	rs7266248	rs7266248	rs7266248	rs7266248
rs73307923	rs73307923	rs73307923	_	rs73307923
rs6011452	rs6011452	rs6011452	rs6011452	rs6011452
rs372721829	rs372721829	rs372721829	_	_
rs10854167	rs10854167	rs10854167	rs10854167	rs10854167
rs34978822	rs34978822	rs34978822	_	rs34978822
rs139337637	-	_	-	-
rs9975728	rs9975728	rs9975728	rs9975728	rs9975728
rs4148974	rs4148974	rs4148974	-	rs4148974
rs5746740	rs5746740	rs5746740	rs5746740	rs5746740
rs5754100	rs5754100	rs5754100	rs5754100	rs5754100
rs3838149	-	_	-	-
rs62237617	rs62237617	rs62237617	-	-
rs5762852	rs5762852	rs5762852	rs5762852	rs5762852
rs140353819	rs140353819	rs140353819	-	-
rs139906882	rs139906882	rs139906882	_	rs139906882
rs138430	rs138430	rs138430	rs138430	rs138430
rs2958663	rs2958663	-	-	-
rs2272805	rs2272805	rs2272805	rs2272805	rs2272805
rs148258173	-	_	_	_
rs2382759	-	-	-	-
rs62588628	-	-	_	_
rs5953379	-	_	_	-
rs5981360	-	_	_	_
rs3213462	-	-	_	-

796

Abbreviations: GWAS, genome-wide association study; SNP, single nucleotide polymorphism. For 797 more details on the SNPs see the GWAS by Ruth et al.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 eTable 2. Association between age at menopause and risk of stroke in EPIC-

798

799 CVD (n=7,883).

Outcome/Age at	No. of	Model 1		Model 2		Model 3	
menopause (vears)	cases	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend
Stroke							
<40	240	1.44 (1.20-1.73)		1.34 (1.10-1.63)		1.37 (1.12-1.67)	
40 to<45	340	1.30 (1.11-1.53)		1.24 (1.05-1.46)		1.25 (1.06-1.47)	
45 to <50	828	1.16 (1.05-1.29)	<0.001	1.13 (1.02-1.26)	<0.001	1.14 (1.02-1.27)	<0.001
50 to <55	1,095	1.00 (0.92-1.08)		1.00 (0.92-1.09)		1.00 (0.92-1.09)	
≥55	235	0.88 (0.73-1.05)		0.87 (0.72-1.05)		0.88 (0.73-1.07)	
per 5 years younger	2,738	1.13 (1.08-1.18)		1.10 (1.05-1.16)		1.11 (1.06-1.16)	
Ischemic stroke							
<40	193	1.52 (1.24-1.85)		1.40 (1.13-1.73)		1.43 (1.15-1.77)	
40 to<45	270	1.34 (1.13-1.59)		1.27 (1.06-1.52)		1.28 (1.07-1.53)	
45 to <50	664	1.17 (1.04-1.30)	<0.001	1.14 (1.01-1.28)	<0.001	1.14 (1.02-1.28)	<0.001
50 to <55	874	1.00 (0.92-1.09)		1.00 (0.91-1.10)		1.00 (0.91-1.10)	
≥55	185	0.85 (0.70-1.04)		0.84 (0.69-1.03)		0.85 (0.70-1.05)	
per 5 years younger	2,186	1.14 (1.09-1.20)		1.12 (1.06-1.17)		1.12 (1.06-1.18)	
Hemorrhagic stroke							
<40	47	1.16 (0.84-1.60)		1.10 (0.80-1.53)		1.13 (0.81-1.57)	
40 to<45	70	1.15 (0.86-1.54)		1.13 (0.84-1.52)		1.13 (0.84-1.53)	
45 to <50	164	1.13 (0.95-1.35)	0.232	1.11 (0.92-1.33)	0.439	1.11 (0.93-1.33)	0.384
50 to <55	221	1.00 (0.86-1.16)		1.00 (0.85-1.17)		1.00 (0.85-1.17)	
≥55	50	0.98 (0.71-1.35)		1.02 (0.74-1.41)		1.02 (0.74-1.41)	
per 5 years younger	552	1.07 (0.99-1.16)		1.05 (0.97-1.14)		1.06 (0.97-1.15)	
Intracerebral hemorrha	ge						
<40	30	1.31 (0.89-1.93)		1.32 (0.89-1.96)		1.34 (0.90-2.00)	
40 to<45	49	1.31 (0.92-1.88)		1.32 (0.92-1.90)		1.33 (0.93-1.91)	
45 to <50	91	1.01 (0.81-1.27)	0.050	1.03 (0.81-1.30)	0.054	1.03 (0.82-1.30)	0.047
50 to <55	147	1.00 (0.83-1.20)		1.00 (0.83-1.21)		1.00 (0.83-1.21)	
≥55	28	0.79 (0.52-1.20)		0.81 (0.53-1.22)		0.80 (0.53-1.22)	
per 5 years younger	345	1.15 (1.04-1.26)		1.14 (1.04-1.26)		1.15 (1.04-1.27)	
Subarachnoid hemorrh	age						
<40	17	0.93 (0.53-1.61)		0.79 (0.44-1.41)		0.81 (0.45-1.45)	
40 to<45	21	0.88 (0.54-1.44)		0.83 (0.51-1.35)		0.84 (0.51-1.36)	
45 to <50	73	1.32 (1.03-1.71)	0.484	1.22 (0.94-1.58)	0.182	1.22 (0.94-1.58)	0.216
50 to <55	74	1.00 (0.77-1.29)		1.00 (0.77-1.30)		1.00 (0.77-1.30)	
≥55	22	1.44 (0.89-2.32)		1.56 (0.95-2.55)		1.55 (0.95-2.55)	
per 5 years younger	207	0.94 (0.82-1.09)		0.89 (0.77-1.04)		0.90 (0.78-1.05)	

800 Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, 801 HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone 802 replacement therapy and age at menarche. Confidence intervals for each age at menopause category 803 are presented using quasi variances in order to enhance the comparison between individual categories. Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for 804 805 linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 eTable 3. Association between age at menopause and risk of stroke in the UK

806

807 Biobank (n=196,361).

Outcome/Age at	No. of	Model 1		Model 2		Model 3	
menopause (vears)	cases	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend	HR (95% CI)	Ptrend
Stroke							
<40	460	1.63 (1.48-1.78)		1.46 (1.33-1.61)		1.45 (1.32-1.59)	
40 to<45	551	1.31 (1.20-1.42)		1.23 (1.13-1.34)		1.23 (1.13-1.33)	
45 to <50	914	1.11 (1.04-1.19)	<0.001	1.08 (1.01-1.16)	<0.001	1.08 (1.01-1.15)	<0.001
50 to <55	1,528	1.00 (0.95-1.05)		1.00 (0.95-1.05)		1.00 (0.95-1.06)	
≥55	579	1.02 (0.94-1.11)		1.01 (0.93-1.10)		1.01 (0.93-1.10)	
per 5 years younger	4,032	1.12 (1.09-1.15)		1.09 (1.07-1.12)		1.09 (1.06-1.12)	
Ischemic stroke							
<40	341	1.65 (1.48-1.84)		1.45 (1.30-1.61)		1.43 (1.28-1.59)	
40 to<45	383	1.25 (1.13-1.38)		1.16 (1.05-1.29)		1.15 (1.04-1.28)	
45 to <50	686	1.15 (1.06-1.24)	<0.001	1.11 (1.02-1.20)	<0.001	1.10 (1.02-1.19)	<0.001
50 to <55	1,121	1.00 (0.94-1.07)		1.00 (0.94-1.07)		1.00 (0.94-1.07)	
≥55	438	1.04 (0.94-1.15)		1.02 (0.93-1.13)		1.02 (0.93-1.12)	
per 5 years younger	2,969	1.12 (1.09-1.15)		1.09 (1.06-1.12)		1.08 (1.05-1.11)	
Hemorrhagic stroke							
<40	119	1.56 (1.30-1.87)		1.52 (1.26-1.82)		1.53 (1.27-1.84)	
40 to<45	168	1.47 (1.26-1.71)		1.44 (1.24-1.68)		1.45 (1.24-1.69)	
45 to <50	228	1.03 (0.90-1.17)	<0.001	1.01 (0.88-1.15)	<0.001	1.01 (0.89-1.16)	<0.001
50 to <55	407	1.00 (0.90-1.11)		1.00 (0.90-1.11)		1.00 (0.90-1.11)	
≥55	141	0.96 (0.81-1.14)		0.97 (0.82-1.16)		0.97 (0.82-1.16)	
per 5 years younger	1,063	1.13 (1.08-1.18)		1.12 (1.07-1.17)		1.12 (1.07-1.18)	
Intracerebral hemorrha	ige						
<40	72	1.62 (1.28-2.04)		1.57 (1.25-1.99)		1.60 (1.27-2.02)	
40 to<45	96	1.41 (1.15-1.73)		1.39 (1.14-1.70)		1.41 (1.15-1.72)	
45 to <50	133	1.02 (0.85-1.22)	<0.001	1.01 (0.85-1.20)	<0.001	1.01 (0.85-1.21)	<0.001
50 to <55	247	1.00 (0.88-1.14)		1.00 (0.87-1.14)		1.00 (0.87-1.15)	
≥55	83	0.86 (0.68-1.09)		0.87 (0.69-1.10)		0.87 (0.69-1.10)	
per 5 years younger	631	1.15 (1.08-1.22)		1.14 (1.07-1.21)		1.14 (1.07-1.21)	
Subarachnoid hemorrh	nage						
<40	47	1.48 (1.10-1.98)		1.44 (1.07-1.93)		1.43 (1.06-1.92)	
40 to<45	72	1.55 (1.22-1.97)		1.52 (1.20-1.93)		1.52 (1.19-1.93)	
45 to <50	95	1.04 (0.85-1.27)	0.009	1.01 (0.83-1.24)	0.023	1.01 (0.83-1.24)	0.028
50 to <55	160	1.00 (0.85-1.17)		1.00 (0.85-1.17)		1.00 (0.85-1.18)	
≥55	58	1.12 (0.86-1.45)		1.15 (0.89-1.50)		1.15 (0.88-1.50)	
per 5 years younger	432	1.10 (1.02-1.19)		1.09 (1.01-1.18)		1.09 (1.00-1.17)	

808 Model 1 is adjusted for age; Model 2 is additionally adjusted for smoking status, body mass index, 809 HbA1c, total cholesterol, and hypertension; Model 3 is additionally adjusted for ever use of hormone 810 replacement therapy and age at menarche. Confidence intervals for each age at menopause category 811 are presented using quasi variances in order to enhance the comparison between individual categories. 812 Age at menopause from 50 to <55 years was used as reference category. Ptrend indicates P-value for

813 linear trend. Abbreviations: CI, confidence interval; HR, hazard ratio. medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 4 eTable 4. Mendelian Randomization analysis on genetically proxied age at

814

815 menopause and risk of stroke.

	Overall		EPIC-CVI	D	UK Biobank		
Method/Outcome –	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	
Stroke							
IVW	0.95 (0.82-1.09)	0.445	1.01 (0.72-1.41)	0.961	0.93 (0.80-1.09)	0.386	
Simple median	1.00 (0.79-1.25)	0.982	1.00 (0.58-1.71)	0.993	1.00 (0.77-1.29)	0.983	
Weighted median	0.98 (0.78-1.25)	0.893	1.11 (0.63-1.94)	0.717	0.96 (0.74-1.25)	0.750	
MR-Egger	0.91 (0.66-1.27)	0.589	0.82 (0.38-1.77)	0.611	0.94 (0.65-1.34)	0.720	
Intercept	1.00 (0.99-1.01)	0.816	1.01 (0.99-1.03)	0.556	1.00 (0.99-1.01)	0.984	
Ischemic stroke							
IVW	0.98 (0.83-1.16)	0.805	1.08 (0.75-1.57)	0.672	0.96 (0.79-1.15)	0.627	
Simple median	0.99 (0.77-1.28)	0.952	1.10 (0.62-1.97)	0.738	0.97 (0.72-1.29)	0.816	
Weighted median	1.06 (0.81-1.39)	0.681	1.25 (0.68-2.29)	0.475	1.02 (0.75-1.38)	0.920	
MR-Egger	1.01 (0.69-1.48)	0.960	0.87 (0.37-2.04)	0.744	1.05 (0.68-1.61)	0.827	
Intercept	1.00 (0.99-1.01)	0.862	1.01 (0.98-1.03)	0.570	1.00 (0.99-1.01)	0.633	
Hemorrhagic stroke							
IVW	0.85 (0.65-1.11)	0.230	0.77 (0.44-1.37)	0.377	0.87 (0.64-1.18)	0.374	
Simple median	0.98 (0.64-1.52)	0.940	1.04 (0.42-2.58)	0.935	0.97 (0.59-1.59)	0.896	
Weighted median	0.86 (0.55-1.34)	0.508	0.81 (0.31-2.15)	0.679	0.87 (0.53-1.44)	0.594	
MR-Egger	0.68 (0.37-1.26)	0.219	0.70 (0.19-2.58)	0.593	0.67 (0.33-1.36)	0.268	
Intercept	1.01 (0.99-1.02)	0.432	1.00 (0.97-1.04)	0.867	1.01 (0.99-1.03)	0.422	
Intracerebral hemorrh	nage						
IVW	0.92 (0.65-1.29)	0.617	0.90 (0.44-1.83)	0.770	0.92 (0.62-1.37)	0.683	
Simple median	1.00 (0.57-1.76)	0.990	1.20 (0.37-3.89)	0.756	0.95 (0.50-1.80)	0.877	
Weighted median	1.11 (0.62-2.00)	0.715	1.28 (0.38-4.26)	0.691	1.07 (0.55-2.08)	0.843	
MR-Egger	0.97 (0.44-2.15)	0.935	0.74 (0.14-3.78)	0.713	1.05 (0.42-2.62)	0.911	
Intercept	1.00 (0.98-1.02)	0.880	1.01 (0.97-1.05)	0.790	1.00 (0.97-1.02)	0.748	
Subarachnoid hemor	rhage						
IVW	0.75 (0.50-1.14)	0.184	0.61 (0.26-1.43)	0.252	0.81 (0.50-1.30)	0.377	
Simple median	0.80 (0.41-1.55)	0.503	0.56 (0.15-2.08)	0.383	0.90 (0.42-1.95)	0.790	
Weighted median	0.64 (0.33-1.24)	0.187	0.56 (0.14-2.19)	0.403	0.67 (0.31-1.43)	0.296	
MR-Egger	0.40 (0.15-1.06)	0.066	0.62 (0.09-4.49)	0.640	0.35 (0.12-1.06)	0.064	
Intercept	1.02 (0.99-1.04)	0.161	1.00 (0.95-1.05)	0.974	1.02 (1.00-1.05)	0.104	

816 Abbreviations: CI, confidence interval; IVW, inverse variance weighted; HR, hazard ratio. HRs are per 817

five years younger genetically proxied age at menopause.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 eTable 5. Stroke risk factors and female-specific factors stratified by fifths of the

818

819 polygenic risk score for age at menopause.

	Polygenic risk score*				
Characteristic	>0.393 to 1.12	>0.275 to 0.393	>0.172 to 0.275	>0.0537 to 0.172	-0.675 to 0.0537
	n=39,128	n=39,127	n=39,127	n=39,127	n=39,127
Stroke risk factors					
Age, years	58.8 ± 6.0	59.4 ± 5.8	59.3 ± 5.7	59.6 ± 5.6	59.8 ± 5.5
Hypertension	19,466 (49.8%)	19,946 (51.0%)	20,012 (51.2%)	20,401 (52.2%)	20,771 (53.1%)
Body mass index, kg/m ²	26.8 ± 5.1	26.8 ± 5.0	26.9 ± 5.0	26.6 ± 5.1	26.8 ± 5.1
Smoking status					
Never	22,352 (57.4%)	22,544 (57.9%)	22,501 (57.8%)	22,596 (58.1%)	22,687 (58.3%)
Ex	13,169 (33.8%)	12,935 (33.2%)	12,990 (33.4%)	12,868 (33.1%)	12,865 (33.1%)
Current	3,419 (8.8%)	3,451 (8.9%)	3,435 (8.8%)	3,457 (8.9%)	3,371 (8.7%)
Total cholesterol, mmol/L	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1	6.2 ± 1.1
HbA1c, %	5.6 ± 0.6	5.5 ± 0.5	5.5 ± 0.5	5.5 ± 0.6	5.6 ± 0.6
Female-specific factors					
Ever use of HRT	20,485 (52.7%)	19,770 (50.8%)	19,355 (49.8%)	19,102 (49.1%)	18,527 (47.7%)
Age at menarche, years	13.1 ± 1.6	13.2 ± 1.6	13.2 ± 1.6	13.2 ± 1.6	13.3 ± 1.6
*A higher polygenic risk score indicates a lower genetically proxied age at menopause. The					

820 821 822 denominator for all percentages was the number of postmenopausal women without missing values in the respective variable. Abbreviations: HbA1c, glycated hemoglobin; HRT, hormone replacement 823 therapy.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0.International license.
 4 eTable 6. Stroke risk factors and female-specific factors stratified by categories

824

825 of age at menopause.

	Age at menopause, years				
Characteristic	<40	40 to <45	45 to <50	50 to <55	≥55
	n=17,461	n=23,508	n=45,778	n=77,933	n=24,415
Stroke risk factors					
Age, years	55.4 ± 7.4	57.5 ± 6.9	58.4 ± 6.1	60.1 ± 4.9	62.3 ± 3.6
Hypertension	8,848 (50.9%)	11,862 (50.7%)	22,156 (48.6%)	39,291 (50.6%)	14,111 (57.9%)
Body mass index, kg/m ²	27.5 ± 5.5	27.0 ± 5.2	26.8 ± 5.1	26.7 ± 4.9	27.2 ± 5.0
Smoking status					
Never	9,238 (53.1%)	12,848 (54.9%)	25,867 (56.7%)	46,662 (60.1%)	14,657 (60.3%)
Ex	5,686 (32.7%)	7,943 (33.9%)	15,137 (33.2%)	25,549 (32.9%)	8,388 (34.5%)
Current	2,463 (14.2%)	2,612 (11.2%)	4,590 (10.1%)	5,489 (7.1%)	1,270 (5.2%)
Total cholesterol, mmol/L	6.0 ± 1.2	6.2 ± 1.2	6.2 ± 1.1	6.2 ± 1.1	6.3 ± 1.1
HbA1c, %	5.5 ± 0.7	5.5 ± 0.6	5.6 ± 0.5	5.6 ± 0.5	5.6 ± 0.5
Female-specific factors					
Ever use of HRT	11,733 (67.6%)	14,204 (60.8%)	22,551 (49.5%)	32,117 (41.4%)	11,898 (48.9%)
Age at menarche, years	12.9 ± 1.8	13.0 ± 1.7	13.1 ± 1.6	13.2 ± 1.6	13.4 ± 1.6

826 The denominator for all percentages was the number of postmenopausal women without missing values 827 in the respective variable. Abbreviations: HbA1c, glycated hemoglobin; HRT, hormone replacement 828 therapy.

Supplemental Figures 829

eFigure 1. Consistency of associations between age at menopause and risk of 830

831 various subtypes of stroke in EPIC-CVD and the UK Biobank.

Outcome/Age at menopause (years)	No. of cases	5	Hazard ratio (95% CI)
Stroke <40	240 460		1.37 (1.12–1.67) 1.45 (1.32–1.59)
40-<45	340 551		1.25 (1.06-1.47) 1.23 (1.13-1.33)
45-<50	828 914	 	1.14 (1.02-1.27) 1.08 (1.01-1.15)
50-<55	1095 1528	 	1.00 (0.92-1.09) 1.00 (0.95-1.06)
≥55	235 579		0.88 (0.73-1.07) 1.01 (0.93-1.10)
per 5 years younger	2738 4032	-⊡- ◆	1.11 (1.06-1.16) 1.09 (1.06-1.12)
Ischemic stroke <40	193 341		1.43 (1.15–1.77) 1.43 (1.28–1.59)
40-<45	270 383		1.28 (1.07-1.53) 1.15 (1.04-1.28)
45-<50	664 686		1.14 (1.02-1.28) 1.10 (1.02-1.19)
50-<55	874 1121		1.00 (0.91-1.10) 1.00 (0.94-1.07)
≥55	185 438	·	0.85 (0.70-1.05) 1.02 (0.93-1.12)
per 5 years younger	2186 2969	_□- ◆	1.12 (1.06-1.18) 1.08 (1.05-1.11)
Hemorrhagic stroke <40	47 119		1.13 (0.81–1.57) 1.53 (1.27–1.84)
40-<45	70 168		1.13 (0.84–1.53) 1.45 (1.24–1.69)
45-<50	164 228		1.11 (0.93-1.33) 1.01 (0.89-1.16)
50-<55	221 407		1.00 (0.85-1.17) 1.00 (0.90-1.11)
≥55	50 141	·	1.02 (0.74-1.41) 0.97 (0.82-1.16)
per 5 years younger	552 1063		1.06 (0.97-1.15) 1.12 (1.07-1.18)
ICH <40	30 72		1.34 (0.90–2.00) 1.60 (1.27–2.02)
40-<45	49 96		1.33 (0.93–1.91) 1.41 (1.15–1.72)
45-<50	91 133		1.03 (0.82-1.30) 1.01 (0.85-1.21)
50-<55	147 247		1.00 (0.83-1.21) 1.00 (0.87-1.15)
≥55	28 83		0.80 (0.53-1.22) 0.87 (0.69-1.10)
per 5 years younger	345 631	 	1.15 (1.04–1.27) 1.14 (1.07–1.21)
SAH <40	17 47	•- □●	0.81 (0.45-1.45) 1.43 (1.06-1.92)
40-<45	21 72	•	0.84 (0.51-1.36) 1.52 (1.19-1.93)
45-<50	73 95		1.22 (0.94-1.58) 1.01 (0.83-1.24)
50-<55	74 160		1.00 (0.77-1.30) 1.00 (0.85-1.18)
≥55	22 58		1.55 (0.95-2.55) 1.15 (0.88-1.50)
per 5 years younger	207 432		0.90 (0.78-1.05) 1.09 (1.00-1.17)
		0.75 1.0 1.5 2.0	

Gray squares indicate results from EPIC-CVD and black dots indicate results from the UKB. The models were adjusted for age, smoking status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at menarche. Abbreviations: CI, 836 confidence interval; ICH, intracerebral hemorrhage; SAH, subarachnoid hemorrhage.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 Figure 2. Observational analyses investigating the risk of different types of

837

838 stroke per five years younger age at menopause across several subgroups.

Subgroup Stroke	Level			Hazard ratio (95% CI)	P-value
Age	<60	-	•	1.13 (1.08-1.18)	0.010
C .	≥60		_	1.08 (1.04-1.12)	
Smoking	Never		-	1.10 (1.05-1.17)	0.799
5	Ex		F	1.09 (1.04-1.14)	
	Current	_	-	1.10 (1.04-1.16)	
Hormone replacement therapy	Never	-	-	1.10 (1.07-1.14)	0.582
	Ever	-	F	1.09(1.06-1.12)	
Type of menopause	Natural	-	-	1.11 (1.07-1.14)	0.498
	Surgical	_	F	1.09 (1.05-1.13)	
Subtotal	0	-	•	1.09 (1.07-1.12)	
Ischemic stroke					
Age	<60	-		1.13 (1.08-1.19)	0.003
9 -	≥60	_	—	1.08 (1.02-1.15)	
Smoking	Never		•—	1.11 (1.02-1.20)	0.773
5	Ex		-	1.08(1.03-1.14)	
	Current	_	-	1.10 (1.04-1.16)	
Hormone replacement therapy	Never	_	-	1.09(1.04-1.14)	0.995
······································	Ever	-	F	1.09 (1.05-1.13)	
Type of menopause	Natural		-	1.11(1.05-1.17)	0.424
Type of menoplated	Surgical		_	1.07(1.03-1.12)	01121
Subtotal	ourgiour	-	•	1.09 (1.06-1.13)	
Hemorrhagic stroke					
Age	<60	_	•	1 12 (1 03-1 21)	0 902
	>60		<u> </u>	1.08(1.01-1.16)	0.002
Smoking	Never	_		1 10 (1 03–1 18)	0.943
onioking	Fx			1 10 (1 01–1 19)	0.040
	Current		—	1.09 (0.98–1.22)	
Hormone replacement therapy	Never	_	.	1 14 (1 06-1 22)	0 175
······································	Ever			1.06(0.97-1.17)	
Type of menopause	Natural		•	1 12 (1 04-1 20)	0 834
.)po or monopadoo	Surgical			1.10 (0.99–1.24)	01001
Subtotal	g	-		1.10 (1.04-1.16)	
Intracerebral hemorrhage					
Age	<60		e	1.20 (1.10-1.32)	0.238
	≥60	_	•	1.11 (1.05-1.19)	
Smoking	Never	_	•	1.13 (1.05-1.22)	0.691
5	Ex	_		1.15 (1.05-1.27)	
	Current			1.16 (1.03-1.31)	
Hormone replacement therapy	Never	-		1.18 (1.09-1.27)	0.342
,	Ever	_	-	1.12 (1.04-1.20)	
Type of menopause	Natural			1.15 (1.06-1.25)	0.835
	Surgical	-		1.17 (1.06-1.28)	
Subtotal	•	-	-	1.14 (1.08-1.20)	
Subarachnoid hemorrhage					
Age	<60			1.02 (0.88-1.17)	0.935
C C	≥60			0.98 (0.75-1.27)	
Smoking	Never			1.02 (0.85-1.22)	0.638
5	Ex	e		0.97 (0.78-1.20)	
	Current	#		1.01 (0.79-1.28)	
Hormone replacement therapy	Never	_		1.05 (0.86-1.27)	0.258
	Ever	e		0.97 (0.78-1.19)	
Type of menopause	Natural	-		1.02 (0.81-1.29)	0.656
	Surgical	← ●		0.99 (0.73-1.34)	
Subtotal	0			1.00 (0.84-1.20)	
				. ,	
		0.75 1.0	1.25 1.5		

839 840 Abbreviations: CI, confidence interval. P-values indicate P-values for interaction for the categorical 841 variables smoking, hormone replacement therapy, and type of menopause. The P-value for interaction 842 for age has been obtained from a model in which age was included as a continuous variable. All 843 analyses were adjusted for the baseline variables age, smoking status, body mass index, glycated 844 hemoglobin, total cholesterol, hypertension, ever use of hormone replacement therapy, and age at 845 menarche, if appropriate.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
 eFigure 3. Flow chart for selection process of SNPs.



Abbreviations: GWAS, genome-wide association study; SNP, single nucleotide polymorphism.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
 eFigure 4. Mendelian Randomization analysis on genetically proxied age at

849

menopause and risk of stroke excluding very rare genetic variants only. 850

Outcome/Method				I	Hazard ratio (95% CI)	P-value
Stroke						
IVW			-		0.96 (0.85–1.09)	0.503
Simple median					0.98 (0.80-1.20)	0.841
Weighted median					1.05 (0.86-1.29)	0.646
MR-Egger (P _{Intercept} =0.866)					0.94 (0.74–1.20)	0.626
Ischemic stroke						
IVW			-		0.99 (0.86–1.14)	0.859
Simple median					1.04 (0.83–1.30)	0.764
Weighted median					1.04 (0.82-1.32)	0.742
MR-Egger (P _{Intercept} =0.943)					1.00 (0.76–1.31)	0.978
Hemorrhagic stroke						
IVW		-			0.87 (0.69-1.10)	0.254
Simple median		_			0.99 (0.67-1.46)	0.949
Weighted median					0.89 (0.60-1.31)	0.558
MR-Egger (P _{Intercept} =0.691)			•		0.81 (0.51-1.27)	0.352
Intracerebral hemorrhage						
IVW		_			0.89 (0.66-1.20)	0.437
Simple median				_	1.02 (0.62-1.68)	0.930
Weighted median					1.20 (0.73–2.00)	0.473
MR-Egger (P _{Intercept} =0.926)				-	0.87 (0.48-1.55)	0.629
Subarachnoid hemorrhage						
IVW			■		0.83 (0.58–1.20)	0.320
Simple median			•		0.80 (0.44-1.44)	0.455
Weighted median				_	0.91 (0.50-1.65)	0.749
MR-Egger (P _{Intercept} =0.585)	-				0.70 (0.34-1.43)	0.326
	0.25	0.50	1.0	2.0		

851 852 853 854

Abbreviations: CI, confidence interval; IVW, inverse variance weighted. Hazard ratios are per five years younger genetically proxied age at menopause. SNPs with minor allele frequencies <0.01 were excluded from this analysis and the analysis included 203 SNPs in total.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.08.23285676; this version posted February 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 5. Mendelian Randomization analysis on genetically proxied age at

855

856 menopause and risk of stroke adjusted for phenotypes related to cardiovascular

857 risk.

Outcome/Method		Hazard ratio (95% CI)	P-value
Stroke			
IVW		0.93 (0.79-1.08)	0.337
Simple median		0.92 (0.72-1.18)	0.512
Weighted median		0.85 (0.66-1.09)	0.202
MR-Egger (P _{Intercept} =0.942)		0.91 (0.64-1.31)	0.629
Ischemic stroke			
IVW		0.95 (0.79–1.14)	0.553
Simple median		0.87 (0.65-1.16)	0.334
Weighted median		0.91 (0.68-1.22)	0.530
MR-Egger (P _{Intercept} =0.963)		0.94 (0.62-1.43)	0.765
Hemorrhagic stroke			
IVW		0.86 (0.64-1.16)	0.321
Simple median		0.90 (0.56-1.47)	0.677
Weighted median		0.75 (0.46-1.23)	0.254
MR-Egger (P _{intercept} =0.871)		0.82 (0.41-1.62)	0.563
Intracerebral hemorrhage			
IVW		0.90 (0.61-1.32)	0.577
Simple median		0.75 (0.40-1.41)	0.371
Weighted median		0.85 (0.44-1.65)	0.638
MR-Egger (P _{Intercept} =0.665)	\longrightarrow	1.07 (0.44-2.59)	0.885
Subarachnoid hemorrhage			
IVW		0.83 (0.52-1.31)	0.417
Simple median	$ \longrightarrow $	1.09 (0.52-2.29)	0.810
Weighted median ——		0.60 (0.29-1.26)	0.180
MR-Egger (P _{Intercept} =0.435)		0.56 (0.19-1.64)	0.292
0.25	0.50 1.0 2.0		

858 859

Abbreviations: CI, confidence interval; IVW, inverse variance weighted. Hazard ratios are per five years 860 younger genetically proxied age at menopause. The analysis was additionally adjusted for smoking 861 status, body mass index, glycated hemoglobin, total cholesterol, hypertension, ever use of hormone 862 replacement therapy, and age at menarche. This analysis included 169,809 participants with complete 863 data on all covariates (4,448 from EPIC-CVD and 165,361 from the UKB).